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1 Abbreviations 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
α Alpha particle radiation 
β Beta particle radiation 
Ab Antibody 
ADCC Antibody dependent cellular toxicity 
ALT Alanine Aminotransferase 
ALP Alkaline Phosphatase 
AST Aspartate Aminotransferase 
AUC Area under the curve 
BUL Blood Urea level 
CDC Complement dependent cytotoxicity 
CDR Complementarity determining regions 
60Co Cobalt 60 
Fab Fragment antigen-binding 
Fc Fragment crystallisable 
FDA Food and Drug Administration 
HAMA Human anti-mouse antibody 
HER2 Human epidermal growth factor receptor 
IgG Immunoglobulin type G 
I.P. Intraperitoneal 
I.V. Intravenous 
LET Linear Energy Transfer 
MAb Monoclonal antibody 
MTA Maximum Tolerated Activity 
MTD Maximum Tolerated Dose 
NK-Cells Natural killer cells 
OC Ovarian carcinoma 
RIC Radioimmunoconjugate 
RIT Radioimmunotherapy 
RBE Relative biological effectiveness 
S.C. Subcutaneous 
x-ray X -radiation 
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3 Introduction 
Surgery and external radiation therapy (ERT) are the main treatment modalities for primary 
(localized) tumors. No curative treatment is available for a large number of patients with 
metastatic adenocarcinomas (e.g. breast and ovarian carcinoma) and squamous cell carcinomas. 
Chemotherapy is often the only option when overt metastases are evident. Treatment aim is 
prolongation of symptom free survival. When micrometastases are present, adjuvant 
chemotherapies are in several cases shown to improve overall survival and are used either alone 
or as a part of combined treatment regimens. Despite dose limiting toxicity and low specificity 
of chemotherapy, prolonged survival can be achieved in a subset of patients. Hence, new 
treatment modalities (e.g. molecularly targeted therapies, immunotherapy, radioimmunotherapy 
(RIT), or gene therapy) are being developed to selectively target the tumor tissue cells and 
stromal components with lower normal tissue injury.  
The aim of RIT is specific tumor cell killing with less collateral damage to the 
surrounding tissue. The aim of this thesis is to test RIT in the form of 227Th-DOTA-trastuzumab 
in mouse models of human breast and ovarian cancers. 
 
 
 
 
 
 
 
 
 
10 
 
3.1  Radioimmunotherapy (RIT) 
RIT can simply be defined as antibody guided radiation therapy. This is an administration of 
monoclonal antibodies or their derived constructs after chemical conjugation to therapeutic 
radioisotopes. In this way, either alpha- or beta-particle emitting radionuclides are 
predominantly delivered to tissues bearing the target antigen.  
 
 
 
Figure 1: Principles of RIT. Systemic injection of radionuclides attached to antibodies 
that bind to tumor cell and selectively irradiates these cells. A radionuclide can either be 
an alpha or beta emitter. 
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3.1.1 Monoclonal antibodies 
Monoclonal antibody is a Y shaped structure with two Fab domains and one Fc domain. The 
two Fab domains, the variable regions of antibody, are responsible for the specific binding to 
the target antigen. The Fc domain, the constant region, is responsible for the activation of 
various component of the immune system.  
                           
Figure 2: Y shaped structure of antibody. The Fc domain consists of the constant part of 
the two heavy chains (dark red), while the Fab domains consists of the variable part of the 
heavy chain (red) and the light chain (blue). The antibody binds to the specific epitope of 
the target protein.  
3.1.1.1 Development of monoclonal antibodies 
Paul Ehrlich (1854-1915), Nobel Prize holding German scientist, along with Emil Behring 
proposed a magic bullet as the treatment of infections [1]. Their ideas not only revolutionized 
the fields of immunology and histology but eventually also led to the invention of 
chemotherapy and radioimmunotherapy. Georges Kohler (1946-1995) and Cesar Milstein 
(1927-2002) shared the Nobel Prize in 1984 on their work of developing the hybridoma 
12 
 
technology for producing antibodies of a single specificity. However, patients treated with 
mouse antibodies developed human anti-mouse antibody (HAMA) response. This is a 
hypersensitivity reaction due to the production of human antibody against the administered 
murine antibody. In order to reduce HAMA, chimeric antibodies were designed through fusion 
of the variable region of the mouse antibody with the constant region of a human antibody. 
HAMA response was further decreased by developing humanized antibodies, retaining only the 
complementarity-determining region (CDRs) of the murine Ab, while more recent methods 
have generated fully human monoclonal antibodies (Figure 3) [2-5]. 
 
 
 
 
 
Figure 3: Most important types of antibodies used in radioimmunotherapy and 
immunotherapy. A) Mouse antibody with heavy chains and light chains and constant 
region. B) Chimeric antibody with replaced constant regions of mouse antibody by their 
human analogous. C) Humanized antibody with 90 to 95 % human. D) Fully human 
antibody (IgG) [6]. 
 
A
B 
C 
D 
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Clinical research based on monoclonal antibody therapy as a single agent or as a 
delivery vehicle for radionuclides was triggered due to development of humanized monoclonal 
antibodies. Many pharmaceutical companies are intensely involved in to improve the 
production of human monoclonal antibodies. The first humanized monoclonal antibody, 
trastuzumab (Herceptin), gained FDA approval in 1998 and recently reviewed [7].  
 
3.1.1.2 Mechanism of action of therapeutic antibodies  
Monoclonal antibodies as a single agent can exert cytotoxic effects on tumor cells after binding 
to their corresponding antigen. Antigen antibody complex leads to the stimulation of two major 
pathways, immune mediated cell killing and inhibition of intracellular growth signals. Immune 
mediated pathway involves effector cells like the natural killer (NK) cells or macrophages or 
the complement system. Effector cells bind to the Fc domain of the antibody, which is attached 
to its corresponding antigen, kill the tumor cell either via lysis or phagocytosis (Figure 4). This 
mechanism is called antibody dependent cellular cytotoxicity (ADCC). The activation of the 
complement cascade triggers the release of chemotactic factors which ultimately form the 
membrane attack complex and lyse the tumor cells (Figure 4). This mechanism is called 
complement dependent cytotoxicity (CDC). Growth inhibitory action of an antibody results 
when the antibody blocks the binding of a ligand to a growth factor receptor.  
14 
 
 
Figure 4: Mechanism of action of therapeutic monoclonal antibodies. The binding of mAb 
to the tumor cell results in immune effector cell migration to their binding site and 
initiation of complement cascade. Tumor cell death occurs either via phagocytosis or lysis 
[6].  
3.1.1.3 Trastuzumab (Herceptin®) 
Trastuzumab (Herceptin®, Hoffmann-La Roche) binds to the HER2 (Human Epidermal Growth 
Factor Receptor) receptor blocks the HER2 mediated down-stream signals, which are 
responsible for cell proliferation and growth, as shown in figure 5. As mentioned above, 
trastuzumab also initiate immune mediated cell killing (Figure 4).  
15 
 
 
Figure 5: Mechanism of action of trastuzumab (Herceptin). HER-2 receptors on the 
tumor cell send proliferative signals from the plasma membrane to the nucleus of the cell 
and are responsible for the growth and proliferation of tumor cells. Trastuzumab not only 
blocks the HER2 signals but also flag the cells for destruction by the immune system [6]. 
 
Trastuzumab, as a single agent or with chemotherapy, is approved for the patients with 
HER-2 expressing metastatic breast cancer. In these patients, trastuzumab treatment resulted in 
a response rate of 12-35 % and in combination with paclitaxel or anthracyclines, the response 
rate increased to 40 % - 60 % [7, 8]. Trastuzumab is also showing clinical activity as 
monotherapy in phase I/II trial in women with HER-2 positive metastatic ovarian cancer [9, 
10]. 
HER2 is a membrane of the human epidermal growth factor receptor family that consist 
EGFR (ErbB-1/HER1), HER2 (ErbB-2) HER3 (ErbB-3) and HER4 (ErbB-4). They comprise 
of an extracellular cellular ligand binding domain and an intracellular domain which is 
responsible for protein-tyrosine kinase activity. These receptors mediate cell growth, 
differentiation and survival. Overexpression of EGFR and HER2 has often been associated with 
malignant transformation and therefore can be considered as potential targets for targeted 
therapies [11, 12].  
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Trastuzumab temporarily stops the tumor growth, when given alone, and the tumor 
continues to grow if the delivery of the drug is stopped. This suggests that HER2 expressing 
tumors could probably be treated in a much better way if trastuzumab carries toxic material like 
radionuclides or if used along with chemotherapy [11, 12].  
One of the necessities of a successful targeted therapy (RIT or Immunotherapy) is that 
the metastatic or disseminated tumors express the target antigen to a similar extent as the 
corresponding primary tumor. It has been seen that in growth factor receptor family, the 
receptor expression at primary tumor are similar to the receptor expression at their 
corresponding metastatic tumor sites [11, 12]. 
It has also been documented that the HER2 receptors are weekly expressed in critical 
normal organs, like liver and various epithelial tissue, and therefore has become a favorable 
target for RIT and immunotherapy. Use of trastuzumab as a carrier for either alpha- or beta-
emitting radionuclides may enhance the effect of the treatment and thus may also allow 
treatment of patients with lower HER-2 overexpression [11, 13]. 
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3.1.2 Structure of radioimmunoconjugates 
A radioimmunoconjugate is typically made by attaching a metallic radionuclide to an antibody 
with the help of a bi-specific chelating agent. The chelator can be covalently linked to lysine 
residue of the antibody (Figure 6). For halogen radionuclides like 131-I, 125-I and 211-At, 
other chemical linkers are used. Halogens can also be directly bound to tyrosine residues on the 
antibody after first being oxidized.  
 
 
Figure 6: Formation of radioimmunoconjugate. Using a chelating linker, first a chelating 
agent is covalently bound to the antibody. Then the chelator binds (chelates) a 
radionuclide, making a complete radioimmunoconjugate [14]. 
 
The chelators are used by two different approaches in RIT; pre-labeling and post- 
labeling. In post labeling approach, a chelating agent is first conjugated to the antibodies before 
its radiolabeling. In pre-labeling approach, a chelator is first labeled with the radionuclides and 
then conjugated to antibodies. We have used both methods for 227Th, but post labeling turned 
out to give the best labeling yields and stability [15]. 
Due to diverse properties and coordination chemistry of radionuclides, it is difficult to 
design a chelating agent which can bind to all radionuclides. Bifunctional chelating agent 
development is dependent on making different derivatives from three well defined inorganic 
chemistry chelating agents; EDTA, DOTA and DTPA. The most common form of chelators 
that are being used in RIT is either DOTA or DTPA derivatives and their structures have shown 
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in figure 7. EDTA derivatives were first developed as bifunctional chelating agent for 131I and 
90Y, but their limited stability led to the development of bifunctional DTPA derivatives. 
Refinements of these DTPA derivatives led to the creation of CHX-A DTPA which has been 
reported to form stable complexes with 131I, 177Lu and 213Bi. This bifunctional chelating agent 
was used in first clinical trial of using 213Bi and 90Y is now part of the commercially available 
radioimmunoconjugate Zevalin. 
However, CHX-A DTPA complex with 111In, 177Lu and 213Bi was less stable than for 
90Y. Therefore, DOTA derivatives were developed for complexing 111In, 86Y, 90Y, 177Lu, 213Bi, 
212Pb and 225Ac. DOTA complexes are generally more stable than DTPA. However, limitation 
of DOTA use is related to its slow complex formation rates which compromise radiolabeling 
yields, efficiency and specific activity. This problem can be overcome by increasing 
temperature provided the conjugate product is heat tolerant.  
The field of bifunctional chelating agent development from DTPA, DOTA and as well 
from others chemical agents is still advancing but it seem little chance of further advancement 
in the stability of DTPA and DOTA [16].  
 
Figure 7 Structure of bi-functional chelating agents [14]. 
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3.1.3 Mechanisms of action in RIT   
The binding of antibody alone to antigen starts multiple mechanisms of tumor cell killing, 
including ADCC and complement system activation, as explained above (see 3.1.1.2). 
Radiolabeled antibody has two advantages over antibody as single agent; 1) Tumor cells not 
expressing the antigen or with unreachable antigen can still be targeted by the radiation emitted 
by the radionuclides (Figure 8 and 9). 2) Antibody -or drug -resistant tumor cells may be 
sensitive to radiation.  
 
Figure 8: Mechanism of action of radioimmunotherapy  
Radiolabeled antibody therapy has an advantage (right) “ with crossed fire” over naked 
or single agent antibody therapy (left) due to killing of cells without binding to their 
corresponding antigen [17]. 
 
The efficacy of RIT depends on number of factors, including the properties of targeted 
antigen (specificity, density, availability, shedding and heterogeneity of expression) tumor 
vasculature (degree of vascularization, blood flow and permeability) the monoclonal antibody 
(specificity, immunoreactivity, stability and affinity) and the properties of chosen radioisotopes 
(emission characteristics and half life) [18]. 
Type of emission is an important physical property of a radionuclide which determines 
the severity of biological effects. Before describing the mechanism of interaction of 
radionuclides with absorbent or medium through which they pass, it is necessary to understand 
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the concept of ionization. When radiation energy is sufficient to eject one or more orbital 
electrons from atom or molecule of absorbing medium, the process is called ionization and the 
radiation is called ionizing. The process of ionization is produced either directly or indirectly. 
Charged particles are directly ionizing radiation [19]. 
Radiobiology is the study of action of ionizing radiation on living things. Directly 
ionizing radiation, in the form of radionuclide (RIT), principally damages the DNA. In addition 
to DNA, mitochondria, lipid membrane and some death receptor in the cell membrane can also 
be targeted by radionuclides. Two major types of DNA damage are produced in RIT; 1) single 
strand DNA breaks (SSB), 2) double strands DNA breaks (DSB). Grossly, radiation induced 
biological changes can be divided into lethal, sublethal and potentially lethal with different out 
comes. Lethal changes are always irreversible and results always in cell death. Sublethal 
changes can be repaired and are not deadly for the cells, but more than one sub-lethal damage 
in a short time can be transformed into a lethal damage. Potentially lethal damage to DNA will 
normally lead to cell death but if the cell gets enough time, the damage can be repaired. RIT 
may also kill tumor cells by bystander effects, the killing of cells not hit by direct radiation but 
by signals from irradiated cells. Further more particulate radiations can hit different regions of 
cell which may give different out come (Figure 9) [20-22].  
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Figure 9: Radiobiology of radioimmunotherapy. Radioimmunotherapeutic agents not 
only irradiate the cells they attached but can also exert cross- irradiation effects and 
bystander effects. The radiation response also depends on the type of target being hit. 
Radiation-sensitive targets in cells include DNA, mitochondria and the lipid membrane. 
Some membrane receptors, including death receptors, can be stimulated by radiation and 
thereby starting downstream cellular signaling pathways [22].  
 
Charged particles are directly ionizing radiation. This means that charged particles have 
sufficient kinetic energy to disrupt the atomic structure of absorbing material through which 
they pass. This interaction generates different kinds of biochemical process. In brief, when a 
charged particle passes through absorbent material, in tissue or cells, two kinds of collisions 
take place; hard collisions and soft collisions [23]. Due to this interaction, the charged particles 
slow down and release its energy along its track. After light collision, the loss of energy takes 
place in a long distance while after hard collision most of the energy is lost at a very short 
distance. This energy loss is determined by the stopping power of medium which indirectly 
determined by charge and velocity of particles [23, 24].  
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Heavy, charged particles (alpha particles) have short range and loose their energy in a 
very short distance while, lighter, charged particles have longer range and loose their energy at 
longer distance. The Bragg curve shows that the energy lost by an alpha particle per unit length 
increases dramatically before it stops. This peak of energy loss is known as the Bragg-peak and 
is characteristic of alpha particles (Figure 10). Figure 10 shows the appearance of the Bragg-
peak along the particle track length which is less than 100 μm in water for alpha particles. 
Thus, when an alpha-particle hits a nucleus and deposits its Bragg peak inside the nucleus the 
chance of cell death is very high. In comparison, several hundred beta particles are necessary to 
give the same amount of damage. 
 
 
 
Figure 10: Energy depositions along the path of an α-particle per unit path. LET vs. 
distance travelled in tissue for α-particles with 2 different initial kinetic energies. α-
particles emitted with lower initial energy are closer to their Bragg peak and, therefore, 
start out with higher LET. LET of electrons with initial energy of 100–500 keV is also 
shown at bottom of plot for comparison [24]. 
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 The term Linear Energy Transfer (LET) is used to describe the density of ionization in 
particle tracks. LET is the average energy deposited by a particle per unit track length traversed 
and is expressed in keV/μm [21].  
Radionuclides are classified as low and high LET emitters depending upon the amount 
of energy released by the emitted particle in tissue (Table 1). Low LET beta-particles produce 
sparse ionization events and individual DNA lesions. However, high LET alpha-particles 
produce densely localized ionizations along a linear track resulting in multiple and severe 
damage of the DNA double strand (Figure 11) [22, 24]. 
                    A                                                                             B 
                                 
Figure 11: Patterns of DNA damage caused by different LET radiation. Low LET beta 
particle radiation, due to sparse or random ionization, produces reparable DNA damage 
(B). On the other hand, high LET alpha particle radiation, due to their dense ionization, 
produces multiple local damaging sites that are poorly reparable (A) [22]. 
  
Toxicity of high LET emitters is independent of oxygen and toxic effects are due to 
direct ionization of DNA. On the other hand, oxygen related free radicals play an important role 
in low LET mediated cellular toxicity [21, 24, 25].  
Different radiation types produce different magnitude of biological response. As the LET 
increases, the probability of radiation induced biological damage also increases. Therefore, a 
term relative biological effectiveness (RBE) was introduced to determine the therapeutic 
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advantages and disadvantages among different radiation therapies (see. material and methods) 
[24].  
Biological response of tissues does not only depend on the quality of radiation and total 
absorbed dose but also depends on dose rate. Radiation dose delivers at high rate decrease 
repair time of tissues. As the dose rate is lowered, time of dose delivery is increased and it 
becomes possible for repair mechanism to take place due to proliferation and possible DNA 
repair. This is an advantage for normal tissue but may be a disadvantage for tumor tissue. 
However, repair mechanism of tumor tissue is not working as normal tissue and therefore, 
repair is less likely since alpha radiation causes mainly irreparable DNA double strand breaks. 
Moreover, the dose rate effect is different from one tissue to another and therefore, it can be 
difficult to assess the efficacy of RIT solely on the basis of dose rates [26]. However, dose rate 
effect in RIT is very significant when compared with external beam radiation therapy. 
Clinically administered dose (X radiation) can be delivered in a very short time by RIT with 
minimum normal tissue toxicity [26, 27]. Therefore, continuous low dose rate give maximum 
normal tissue sparing and decrease tumor cell proliferation [27].   
. 
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3.2 High and low LET emitting radionuclides used in RIT 
The selection of radionuclides for RIT must be based on their physical and chemical properties, 
including their half-life, LET, gamma emissions for imaging and chemistry for binding to 
antibody. In addition, economic considerations, including cost of production and availability of 
radionuclides plays also an important role during radionuclide selection [28].  
 
Table 1 High and Low LET emitting radionuclides used in RIT 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Isotopes Half -life Maximum Energy (keV) 
Maximum 
Range (mm) Emission 
Low linear energy transfer (LET 0.2 keV/μm) emitters 
90Y 2.67 days 2.284 12 Beta 
131I 8.4 days 606 2-3 Beta, gamma, X ray 
177Lu 6.7 days 497 < 2 Beta, gamma, X ray 
67Cu 2.5 days 575 2.3 Beta, gamma, X ray 
186Re 3.7 days 1.077 4.8 Beta, gamma, X ray 
188Re 17.0 h 2.120 10.4 Beta, gamma, X ray 
High linear energy transfer (LET 50–230 keV/μm) emitters 
225Ac 10 days 6-883 <1 Alpha, gamma, X ray 
211At 7.2 h 6.867 <1 Alpha, gamma, X ray 
213Bi 46 min 8.377 <1 Alpha, gamma, X ray 
227Th 18.7 days 5.900 <1 Alpha, gamma 
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3.2.1 Low LET emitting radionuclides 
Beta emitters, including 131I, 90Y, 177Lu, 188Re, 186Re, and 67Cu, have been in great focus from 
the last few decades and some of them have been approved for radioimmunotherapy (Zevalin 
and Bexxar) and the rest are in clinical trials. Their physical half-life ranges from 17 hours to 
193 hours and the amount of energy released by particle ranges 575 keV to 2.284 keV. All the 
most commonly used beta emitters also emit gamma radiation, except 90Y. Gamma rays allow 
external imaging (Table 1) [14, 22]. 
The availability and long experience with radiolabeling chemistry of beta emitters play 
an important role in their wide use. Iodine -131 has a half life of almost 8 days and emits 606 
keV energy beta particles with a range of 2-3 mm. Its high gamma radiation yield result in 
isolation of the patient for about a week after treatment. 
Yttrium-90 has a short half life of almost 2.6 days and emits 2.284 keV energy within a 
range of 12 mm. It has a high energy emission and prolonged tumor retention compared to 131I. 
However, bone marrow toxicity due to the long range is a disadvantage.  
Lutetium -177 and copper-67 have shown some advantages over other beta emitters due 
to deposition of high energy in a considerably short range. Lutetium -177 emits 497 keV energy 
in a range of less than 2 mm and in almost same range (2.3 mm), copper-67 (has half life of 2.5 
days) emits 575 keV energy. Both radionuclides have been tested recently in both clinical and 
preclinical research and showed quite promising results [14, 29, 30]. Rhenium-186 has a half 
life of 3.7 days and emits 1.077 keV energy in a range of 4.8 mm is commonly used against 
bone metastasis of breast and ovarian cancers and arthritis [31]. Rhenium-188 has a half life of 
17 hours and emits 2.120 keV energy in a range of 10.4 mm and showed considerably good 
results in leukemic patients [32].  
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3.2.2  High LET emitting radionuclides 
Currently, only four alpha particle emitting radionuclides are being widely studied in both 
clinical and/or preclinical trials of RIT (Table 1) [22]. Actinium-225 has a half life of 10 days 
with alpha energy emission 6.883 keV, 211At has a half life of 7.2 hours with alpha energy 
emission of 6.867 keV, 213Bi has a half of 46 min with alpha energy emission of 8.377 keV and 
227Th has a half life of 18.7 days and emits with minimum energy of 5.900 keV alpha particles. 
Both the 227Th and the 225Ac nuclides, however, have a relatively large number of α-emitting 
daughter nuclides, which will detach from the radioimmunoconjugate and redistribute in the 
body after the first α-emission [28].  
The progress towards clinical application of α-emitters has been halted by the low 
availability of radionuclides with proper physical and chemical characteristics. Also, because of 
short half-lives and/or limited chemical yields, the production of a final product in clinically 
useful quantities has been challenging. Therefore, attention has been brought to alpha-emitters 
that can be prepared in large quantities from long term operating generators such as 227Th 
generated from 227Ac [22, 28]. 
3.2.2.1 Thorium-227 
Thorium-227 can be produced in clinically relevant amounts from 227Ac, which is generated by 
thermal neutron irradiation of 226Ra. The yield of 227Th purification by anion exchange 
chromatography is almost quantitative [15]. 227Th decays via its alpha- and beta-emitting 
daughters (5 α particles and 2 β particles) including, 223Ra (t½=11.4 d), 219Rn (t½= 4.0 s), 215Po 
(t½= 1.8 ms), 211Pb (t½= 36.1 m), 211Bi (t½= 2.2 m) and 207Tl (t½= 4.8 m) to stable 207Pb (Figure 
12 and Table 1) [33].  
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Figure 12: Decay scheme of 227Th. Thorium-227 decays via its alpha and beta emitting 
daughters, including 5-alpha and 2- beta. Most of the 227Th- daughters have short half-
lives except 223Ra. 
 
It should be noted that the half-life of 223Ra is much longer than that of 221Fr, the 
daughter for 225Ac, and allowing more than sufficient time for blood elimination before decay. 
227Th can be stably conjugated to antibodies with the p-SCN-benzyl–DOTA chelator in a two 
step procedure [15]. In vivo testing of 227Th started in 2004 [34]. Although 227Th can be 
produced in clinically relevant amounts and have been shown to be an efficient and safe nuclide 
in lymphoma, breast cancer and ovarian cancer preclinical models, no clinical studies have yet 
been started [33-40].  
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3.3 Pre clinical experience of high and low LET RIT targeting HER2 
positive carcinomas  
177Lu has been tested in HER2 positive tumor models [41-43]. 177Lu-labeled trastuzumab or 
pertuzumab has shown growth inhibition of HER2 positive breast and ovarian cancers and 
improved the survival of mice [41, 42, 44]. 
The efficacy of 225Ac was compared with 213Bi and 90Y after conjugating to the anti-
HER2 antibody (7.16.4) in a mouse model HER2 positive (NT2.5 cell lines). 225Ac was much 
more effective than 213Bi and 90Y labeled anti-HER2 antibodies in tumor eradication and 
prolongation of survival mouse [45]. 
The efficacy of 211At-labeled trastuzumab was evaluated in a rat model of breast 
carcinomatous meningitis (CM) (MCF7 cells). The median survival increased significantly after 
211At-labeled trastuzumab in comparison to the control. For animal receiving 33 and 66 μCi of 
211At-trastuzumab, the median survival was 45 and 48 days, while for animal receiving saline 
and cold trastuzumab groups, the median survival was 21 days [46]. The effect of 211At-
trastuzumab as a single therapy and fractionated therapy was compared with different dosages 
of cold trastuzumab in mice bearing (SKOV-3 xenografts). The combination of 500 μg 
trastuzumab and 400 kBq 211At-trastuzumab had the greatest effect, with complete eradication 
of the tumors [47]. The efficacy of 213Bi-conugates (trastuzumab and CC49 mAb antibody) was 
determined in a rat bearing (LS-174 T cells). The results showed that the maximum tolerated 
dose was 500 μCi/mice and prolonged the median survival to 41 days as compared to 28 days 
of control. The dual targeting effect of 213Bi after conjugated to trastuzumab and CC49 mAb 
against the tumor associated glycoprotein was tested. The administration of 213Bi-trastuzumab 
followed by the injection of 213Bi-antiglycoprotein antibody resulted in greater therapeutic 
effects (therapeutic index of 9.8), as compared to single injection, and prolonged the survival of 
mice [48].  
Our group has evaluated the therapeutic efficacy of 227Th-trastuzumab on SKBR-3 and 
SKOV-3 both in vitro and in vivo [35, 36, 39, 40]. In addition, 227Th-rituximab against CD20 
on NHL has been evaluated both in vitro and in vivo [33, 34, 38, 49, 50]. 
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3.4 Clinical experience of high and low LET RIT  
3.4.1 Clinical experience of high and low LET RIT in haematological cancers 
Non Hodgkin lymphoma (NHL)  
The first clinical trial of NHL patients was performed with anti-HLA-DR mAb after labeling 
with Iodine-131 in 1988. Complete or partial remission in 4 out of 10 patients with minimal 
toxicity was seen in most of the patients [51]. Anti-CD20 antibodies labeled with 131I were used 
in patients for the first time in 1993. After treatment and bone marrow reinfusion, the complete 
remission was seen in 16 patients and partial response was seen in 2 out of 19 patients with 
bone marrow toxicity [52]. Anti-CD37 phase I clinical trials investigating the biodistribution, 
therapeutic efficacy and toxicity of 131I-MB-1 were reported in 1989 [53] and in 1992 [54] for 
NHL patients. 40 % of the patients experienced complete remission after 131I- MB-1 with mild 
bone marrow suppression. 90Y-hLL2 has been used against CD22 positive NHL [55]. A 
multicenter trial performed by Morschhauser et al showed that fractionated anti-CD22 therapy 
with 90Y-hLL2 resulted in durable complete response and suggested a recommended dose of 22 
mCi/m2 in every second week for future studies [55]. A study performed by Linden et al. 
concluded that weekly fractionated RIT with 90Y-hLL2 (5 mCi/m2 or 185 MBq/m2) showed 
highest response of 62 % with complete remission, with minor bone marrow toxicity [56].  
In 2002 and 2003, 90Y-ibritumomab tiuxetan (Zevalin) and 131I-tositumomab (Bexxar), 
were approved by FDA for the treatment of relapsed and refractory low grade, follicular or 
transformed B-cell lymphoma (NHL) [57]. A complete response rate of 20-49 % and overall 
response rate of 60–80 % with mild toxicity was observed with Zevalin [58]. Zevalin was 
approved as first line therapy in Europe in 2008 [57, 59]. Promising complete response rates of 
50 to 75 % were observed with Bexxar in NHL patients [60, 61]. RIT against lymphoma is 
considered as combination therapy with chemotherapy or as consolidation therapy. 
Myeloid leukemia  
The efficacy of anti- CD45, CD66 and CD33 RIT have been evaluated in combination with 
chemotherapy in these patients AML and CML patients [32, 62-65]. Advanced AML patients 
treated with (122-437 mCi/m2) 131I-labeleld M195 and Hum195, against CD33, in combination 
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with chemotherapy resulted in median survival of 4.9 (range 0.3-90 months) [62]. Pagel et al in 
his first clinical trial estimated that 3 year disease free survival was between 21 % to 61 % and 
in his second trial estimated 1 year survival was more than 41 % [63, 64]. In other study, 20 
patients treated with 131I-labeled anti CD45 along with chemotherapy showed median disease 
free survival of 17 months after bone marrow toxicity [66]. CD66 antigens in myeloid leukemic 
patients were also used as target antigen and 188Re and 90Y-labeled anti-CD66 antibodies were 
used in phase I and II clinical trials. The probability of survival was estimated to be 70 % at 1 
year and 52 % at 2 years [32, 65].  
Clinical trials with high LET alpha emitting 213Bi- labelled HUM195 anti-CD33 showed 
quite promising results, especially due to decrease bone marrow toxicity [67, 68]. A study 
performed by Jurcic et al in 2002 included 18 patients with relapsed and refractory AML and 
CML and treated with 213Bi-HuM195. All developed myelosuppression with a median time 
recovery of 14 days and 93 of patients showed reduction in circulating blast [67]. In a recent 
phase 1 and II trials, maximum tolerated dose and anti-leukemic effects of 213Bi-HuM195 were 
determined in patients after partial cytoreductive chemotherapy. In these studies MTD was 37 
MB/kg along with median response duration of 6 months (range, 2-12 months). Dose limiting 
myelosuppression was last for 35 days [68].  
3.4.2 Clinical experience of high and low LET RIT in carcinomas 
The first clinical trial of RIT in solid tumor was performed by Welt et al in 1990. In this study, 
biodistribution and imaging characteristics of 131I were studied after binding to anti-A33 
antibodies in colorectal carcinoma patients. Selective localization to tumor tissue was seen in 
19 of 20 patients [69]. According to a recent review, a total of 58 clinical trials have been 
preformed to evaluate the efficacy of RIT against 15 different tumor targeting antigens in 
gliomas, colon, ovarian, gastric, liver, lungs, renal, breast, brain and in some gastrointestinal 
malignancies [22]. Tumor-associated glycoprotein 72 (TAG) and carcinoembryonic antigen 
(CEA) were the main target antigens in these studies and are widely expressed in all the above 
mentioned tumor types [22]. Only few clinical trials for RIT went beyond phase II showing that 
RIT for patients with solid tumors are more challenging than patients with haematological 
cancers [22]. 
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However, in 2005, a phase II clinical study was performed to target CEA antigen with 
131I-labetuzumab in patients with metastatic colorectal carcinoma. Study showed quite 
promising results with median overall survival of 68 months and median disease free survival 
of 18 months. The 5 year survival rate was 51.3 % [70]. One year later a phase III clinical trial 
was reported by Verheijen et al with 90Y-labeled HMFG1 murine monoclonal antibody in 
ovarian cancer patients. This study was a multi-central trial with the aim to compare the 
standard treatment plus RIT with standard treatment alone. The end points were survival and 
relapse and safety and no difference was found between standard treatments and RIT treatment 
[71]. 
Limited numbers of clinical trials have evaluated the alpha-particle based RIT in solid 
tumors. Zalutsky et al. investigated the efficacy and safety of 211At-labeled ch81C6 in patients 
with recurrent malignant brain tumors. This study demonstrated that the regional administration 
of 211At-labeled ch81C6 was safe, 96.7 % decay was localized, and was therapeutically 
beneficial with pronged survival of 1-3 years [72]. Anderson and co-workers at university of 
Gothenburg, Sweden, investigated 211At-MX35 F (ab)2 in ovarian cancer patients. This phase I 
study demonstrated that intraperitoneal administration of 211At-MX35 F (ab)2 was feasible to 
achieve therapeutic doses to microscopic tumor cluster without significance toxicity [73]. 
The limited success of RIT for solid tumors in clinical trials can be explained by the fact 
that radiation dose delivery by RIT to the tumor is not enough to overcome the radioresistance 
of solid tumor mass [22, 74, 75]. Tumors treated with external beam radiation therapy showed 
clinical response with radiation absorbed dose of 50 Gy to the tumor [22]. However, in clinical 
studies with 90Y-CC49, 131I -CC49 or 131I-MN14 the maximum dose to tumor was between 1.8 
and 33 Gy [76, 77]. Radiation dose to the tumor by RIT is very variable and can in some cases 
be too low to eradicate the tumor.  
Different strategies have been considered or are being developed to find a way to 
improve radiation dose delivery to the solid tumors or their eradication. These strategies 
include; finding ways to improve antibody uptake into the tumor and its uniform distribution, 
and choosing antibodies which themselves can affect the growth of tumor. Tumor uptake of 
radiolabeled antibodies can be improved either by modifying its route of administration 
(locoregional administration in RIT enhances tumor uptake) or by modifying vascular 
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properties of tumors through hyperthermia, radiation and biologically active compounds. In 
addition, it has been found that radioimmunotherapy of solid tumors can be more effective if it 
is combined with chemotherapy. Recently, few clinical trials combining RIT with 
chemotherapy have shown considerably good results [75, 78-81]. 
3.5 Breast Carcinomas 
Breast cancer is the most frequent malignancy and the leading cause of cancer related death in 
women all over the world, with an estimated 23 % of the total new cancer cases and 14 % of the 
total deaths in 2011 or 2010 [82]. In Norway, the incidence of breast cancer has increased over 
the last few decades [83]. However, breast cancer mortality in Norway has been declining in the 
last 15 years are so.  
The treatment options are determined by the multiple factors, including patient age, 
disease stage, histological type of tumor and presence and absence of tumor markers [84-86]. 
Therefore, therapy often is a multi-modal approach, including surgery, chemotherapy, 
hormonal therapy, radiation therapy and targeted therapy [87, 88].  
Surgery is the best option if the disease is localized or has spread to regional lymph 
node and the options are lumpectomy or mastectomy [89]. Chemotherapy and external beam 
radiation therapies can be used adjuvant treatment along with surgery or as single approach, 
depending on the stage and extent of disease [90].  
Hormonal therapy is based on patient age and sex and its intention is to block the effects 
of estrogen and progesterone receptors on the tumor cells, which are known to accelerate cancer 
growth. Hormonal therapy considerably improves the survival and quality of life in patients 
with metastatic breast carcinomas [90, 91]. Targeted therapy is available in the form of 
trastuzumab (Herceptin®); see (3.1.1.3, trastuzumab). HER2/neu overexpression is linked with 
bad prognosis and poor survival [92]. One quarter of breast cancer patients overexpresses 
human epidermal growth factor receptor-2 (HER-2/neu) at their primary and distant tumor sites 
[12]. 
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3.6 Ovarian carcinomas 
Ovarian cancer is the sixth most common cancer world wide with estimated new cases of 
225,500 [82]. More than 140.000 women died and approximately 230.555 cases were 
diagnosed in 2007 [93]. 
In Norway, a total of 4570 new cases of ovarian cancer were reported from 1999 to 
2008 and the age adjusted incidence rates ranged from 10.8 to 13.8 per 100,000 person-years 
[83]. 
Ovarian cancer is mostly sporadic. Due to lack of specific symptoms, 67 % of the 
patients in USA were diagnosed at the stage III and IV. Therefore, surgery followed by 
adjuvant chemotherapy is the standard method of treatment.  
Chemotherapy is always indicated after surgery in the form of paclitaxel. The routine 
treatment includes paclitaxel in combination with a platinum-based compound or platinum 
based therapy alone. Platinum-based chemotherapy alone or in combination with paclitaxel has 
been conformed to significantly improve the survival of OC patients [9, 94-96]. However, 
despite most of the patients have shown response to these above mentioned treatment strategies, 
relapse is still a big problem [9, 97].  
Herceptin® (see 3.1.1.3) have shown clinical activity as monotherapy in phase I/II trial 
in women with HER-2 positive metastatic ovarian cancer [10]. 
Patients with early-stage OC had five year survival rates in the range of 71-93 %, 
whereas in patients with advanced ovarian cancers, survival rate was around 31% [98].  
Overexpression of HER-2 has been reported to be a bad prognostic factor in both early and 
advanced stage disease [99, 100]. Human epidermal growth factor receptor (HER-2, also called 
ErbB-2) is overexpressed in 10 % of ovarian cancer patients [100]. 
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4 Aims of the study  
 
The purpose of this study was to investigate the in vivo stability, therapeutic and toxic effects of 
DOTA-trastuzumab labeled with thorium-227 and to compare this high-LET RIC with the low-
LET beta-emitting 177Lu-RIC using both ovarian and breast cancer tumor models. 
This study investigated the following questions: 
1. Is the administration of the alpha-particle emitting radioimmunoconjugate 227Th-trastuzumab 
safe and therapeutically effective in mice with HER2-overexpressing breast and ovarian cancer 
xenografts? 
2. Is the administration of the high-LET alpha-particle emitting radioimmunoconjugate 227Th-
trastuzumab therapeutically more effective and less toxic than low –LET beta particle emitting 
177Lu-trastuzumab in HER2-overexpressing breast and ovarian cancer xenografts?  
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5 Experimental methods 
5.1 Radioimmunoconjugates preparation  
Alpha radioimmunoconjugates (227Th-DOTA-trastuzumab and 227Th-DOTA -rituximab) were 
prepared at Algeta ASA and transported to the Norwegian Radium Hospital. Radiolabeling of 
freeze dried DOTA-trastuzumab, delivered by Algeta ASA, with beta-radionuclide 177Lu 
conjugate was performed at our institute.  
5.2 Animal and tumor model 
Female Balb/C nu/nu (NCR) mice, with an average weight of 19 to 25 g at the start of study, 
were used in all experiments. Mice were provided by the Department of Comparative Medicine 
Radium Hospital, Oslo University Hospital, Oslo, Norway. All procedures and experiments 
involving animals in this study were approved by the National Animal Research Authority and 
carried out according to the European Convention for the Protection of Vertebrates used for 
Scientific Purposes. The animals were maintained under pathogen-free conditions, and food and 
water were supplied ad libitum. 
Mice were anaesthetized before tumor implantation. A mixture of 2.4 mg/ ml and 2.4 
mg (Zoletil® vet, Virbac, Carros Cedex, France) was used for anaesthesia of mice. The dose 
used was between 0.05-0.1 ml/animal (Paper 1, 2 and 3). Breast and ovarian cancer tumor 
xenografts were implanted in mice 2 to 3 weeks before the start of experiments. The 
xenografted tumor line originated from HER-2 positive breast and ovarian cancer (SKBR-3 and 
SKOV-3) cells from American Type Culture Collection (ATCC, Manassas, VA). All animals 
were euthanized by cervical dislocation at the end of experiment. 
5.3 Biodistribution and dosimetry  
The conjugates 227Th-trastuzumab, 227Th-rituximab and 177Lu-trastuzumab were administrated 
by tail vein injection in 100μL solution to each tumor bearing animal. Different time points 
were decided for each conjugate and a total of four to six animals were autopsied at each time 
points. 
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Tumors and organs were collected, weighted and measured for radioactivity content. 
The cumulated activity in various organs, from the time of injection of preparation until no 
activity was left in the body, was estimated by calculation of the area under the activity 
concentration versus time curves (AUC) (Paper 1, 2 and 3).  
Absorbed radiation dose was estimated using cumulated activity calculated from 
biodistribution data, assuming a complete absorption within the source tissue of the emitted 
particle. For 227Th, no cross radiation was taken into count and it was assumed that there is 100 
% and uniform dose distribution into the tissue. While, for 177Lu cross radiation was taken into 
count as a tissue factor. This is a reliable method used in the animal research. However, this 
method can be improved by including tissue autoradiography to obtain more information about 
tissue activity distribution. Some centres used SPECT to determine the actual tissue activity 
concentration and associated total volume over which the activity is distributed [101, 102].  
5.4 Therapy and toxicity  
Tumor (SKBR-3 and SKOV-3) bearing mice were injected with a single dose of NaCl and 
different dosages of cold trastuzumab and 227Th-trastuzumab, 227Th-rituximab and 177Lu-
trastuzumab in100μL solution. Therapeutic effects were determined by tumor growth and 
survival assessment of mice after treatment. Tumor growth and survival of mice were assessed 
3 times a week for three weeks after injection and thereafter, growth and survival were assessed 
twice a week. Mice with tumor volume larger than 20 mm were killed (Paper 1, 2 and 3). 
Toxicity was evaluated by measuring weight changes in mice after treatment, including 3 
times a week for first three weeks after treatment and thereafter 2 times a week. Blood cell 
counts, white blood cell and platelet counts were measured before and at three different time 
points after treatment, including at the time of autopsy, to assess the therapeutic toxicity. In 
addition, liver enzymes and kidney functions were assessed to evaluate the therapy related 
toxicity (Paper 1, 2 and 3). 
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5.5 Relative biological effects and therapeutic index 
Relative biological effects (RBE) compare the dose of test radiation to the dose of standard 
radiation to produce the same effects.  
RBE = Dose from standard radiation to produce a given biological effect/ Dose from test 
radiation to produce the same biological effect  
Type of radiation used for reference radiation is usually X or 60Co-γ-radiation. In this 
study, however, the low LET RIT was used as reference for the high LET RIT. RBE was 
calculated by dividing the dose for 227Th-trastuzumab by the dose for 177Lu-trastuzumab to 
reach the same end point, which was the difference in the therapeutic efficacy after 
administration of both RICs. Therapeutic efficacy was estimated by plotting the treatment–
induced percent increase in number of days to grow to 500 mm3 and/or 1000 mm3 against the 
cumulative absorbed radiation dose. Anti-tumor effects and bone marrow toxicity are the two 
most commonly used end points to determine RBE in most in-vivo studies [28]. RBE is useful 
preclinical information that can be taken into consideration when designing clinical trials of a 
RIC [28]. However, RBE depends on the quality of radiation, end point and dose rate. 
Therefore, it is some times challenging to compare the various treatments with respect to RBE. 
 Therapeutic index is the percent of tumor control that can be achieved for a given level 
of normal tissue damage [19] and might be a more clinically relevant parameter to compare 
different RITs. In this study a 50 % decrease of WBC was used as a parameter for normal tissue 
damage. The therapeutic index also varies with dose rate, LET and the design of experiments. 
Therefore, therapeutic index in clinical studies will be different from preclinical studies.   
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6 Summary of papers 
 
6.1  Paper 1 
This study was designed to investigate biodistribution, normal tissue toxicity and therapeutic 
efficacy of low dose rate alpha particle emitting radioimmunoconjugate 227Th-trastuzumab in 
mice with HER2 positive breast cancer xenografts. For comparison purpose, the mice bearing 
SKBR xenografts were injected with anti-HER2 antibody trastuzumab alone, 227Th-rituximab 
(non-targeted) and normal saline.  
A significant dose dependent tumor growth inhibition was observed with different dosage 
of 227Th-trastuzumab (200, 400 and 600 kBq/kg) but anti-tumor effects were not seen with non-
targeted 227Th-rituximab (400 and 600 kBq/kg) and trastuzumab alone. Absorbed radiation dose 
to the tumor was approximately 3 Gy after administration of 400 kBq/kg 227Th-trastuzumab. No 
serious bone marrow and normal organ toxicity was seen after the administration of 227Th-
trastuzumab except a transit reduction of leukocyte count in highest dose-group. This study 
came up with the conclusion that the 227Th-trastuzumab therapy not only was effective and well 
tolerated in mice bearing breast cancer xenografts but also warrant the further preclinical 
studies aiming at a clinical trail in breast cancer patients with bone metastasis.  
 
6.2 Paper 2 
In this study, HER2 positive ovarian carcinomas bearing mice were injected with low dose 
alpha particle emitting 227Th-trastuzumab and beta-particle emitting 177Lu-trastuzumab and 
evaluated for their biodistribution (specific and non specific distribution), therapeutic efficacy 
along with bone marrow and normal organ toxicity.  
The absorbed radiation dose to the tumor was 4 Gy after the administration of 400 
kBq/kg of 227Th-trastuzumab and 72 MBq/kg 177Lu-trastuzumab, respectively. The therapeutic 
efficacy, as growth inhibition and growth delay, was better after 227Th-trastuzumab therapy as 
compared to the control, trastuzumab alone, non- tumor binding 227Th-rituximab and 177Lu-
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trastuzumab therapies. Mean survival of mice after treatment with 227Th-trastuzumab was 
significantly improved compared to control and other radioimmunoconjugates (p < 0.05, 
Kaplan Meier). Treatment related bone marrow and normal organ toxicities were not observed 
except for a transient decrease of leukocyte count between 3 to 9 weeks after highest 
administrated dosages of 227Th-trastuzumab. The study showed that alpha emitting RIC 227Th-
trastuzumab therapy improved the survival of mice and effectively inhibited the tumor growth 
as compared to 177Lu-trastuzumab. These results suggest further clinical testing of this RIC 
(227Th-trastuzumab) in patients with micro-metastatic ovarian carcinoma. 
 
6.3 Paper 3 
This study was designed to compare the invivo investigations, including biodistribution, 
therapeutic efficacy and toxicity, of a low dose alpha particle RIT (227Th-trastuzumab) with 
beta particle RIT (177Lu-trastuzumab) in mice bearing breast carcinoma xenografts. 
The absorbed radiation dose to the tumor was approximately 3 Gy after the 
administration of 400 kBq/kg of 227Th-trastuzumab and 40 MBq/kg 177Lu-trastuzumab, 
respectively. Tumor growth was significantly controlled with improved survival at injected 
dosage of 400-1000 kBq/kg 227Th-trastuzumab and 200 MBq/kg of 177Lu-trastuzumab as 
compared to control. Relative biological effectiveness was also calculated to compare the 
therapeutic efficacy of 227Th-trastuzumab with 177Lu-trastuzumab. When compared at same 
therapeutic effect (100 % increases in growth delay) 227Th-trastuzumab was 3 times more 
effective than 177Lu-trastuzumab. On the basis of temporary decrease of WBC, therapeutic 
index of 177Lu-trastuzumab was superior to that of 227Th-trastuzumab. 
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7 Discussion 
This study of high LET alpha-particle emitting 227Th- trastuzumab and low LET beta-particle 
emitting 177Lu-trastuzumab includes biodistribution, tumor targeting and normal tissue toxicity 
in mice with HER 2 positive breast and ovarian cancer xenografts. The concentration of 227Th- 
and 177Lu-labeled-trastuzumab followed a bell shaped curve in tumor tissue as a function of 
time, and the concentration in tumor tissue was significantly higher than in normal tissue. The 
daughter nuclide of 227Th, 223Ra, partly relocated after decay of 227Th to bone tissue, was partly 
internalized by the tumor cells or trapped in the tumor tissue and was partly excreted. 
Therapeutic effect of 227Th-trastuzumab was observed as dose dependent growth inhibition with 
improvement in survival for both tumor models. Beta emitting 177Lu-trastuzumab was also 
effective; however at the same absorbed radiation dose to the tumor, 227Th-trastuzumab efficacy 
was superior to 177Lu-trastuzumab, for both models. On the contrary, when compared at doses 
giving the same temporary decrease of WBC, the therapeutic index of 177Lu-trastuzumab was 
superior to that of 227Th-trastuzumab in the breast cancer model. Mild bone marrow toxicity 
(transient decrease of WBC count) was the only side effect observed with the highest doses of 
both RICs except 1000 kBq/kg of 227Th-trastuzumab where weight loss was observed in few 
animals.  
7.1 Treatment of mice with breast cancer and ovarian cancer 
xenografts with 227Th-trastuzumab 
Dose dependent growth inhibition of breast and ovarian tumors was seen after 227Th-
trastuzumab. 227Th-trastuzumab at dosage of 400-600 kBq/kg in both tumor models and 1000 
kBq/kg in SKBR-tumor model showed improved anti-tumor effects. The lowest administered 
dose of 200 kBq/kg gave variable results against breast cancers and was not effective against 
ovarian cancers, even though absorbed radiation dose to breast tumors was lower (1.5 Gy) than 
ovarian (2 Gy) (Table 2). Higher dosages (400-600 kBq/kg, 227Th-trastuzumab) demonstrated 
relatively better anti-tumor effects against breast carcinomas as compared to ovarian 
carcinomas. However, absorbed radiation doses to the breast tumors (3 Gy and 4 Gy) were 
lower than the ovarian tumor (4 Gy and 6 Gy) as shown in Table 2. Similar methods used for 
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the calculation of absorbed radiation dose to both tumors but cell geometry was not taken into 
consideration. From in vitro microscopy we know that SKOV-3 cells are larger than SKBR-3 
cells and that can have an impact on the absorbed radiation dose since the probability of hitting 
the nucleus will be lower in larger cells than a small cell if the nucleus is of the same size [39]. 
In addition, SKOV-3 cells in culture had a weaker expression of HER2 as compared the SKBR-
3 cells. This does not fit well with the higher dose calculated for the SKOV-3 tumors. We 
observed that the ovarian tumors were more resistant to the 227Th-trastuzumab than breast 
tumors. Inherent difference in radiosensitivity between breast and ovarian malignancies could 
be an explanation for variability (breast more radiosensitive than ovarian) [103]. Moreover, it 
has been shown that the proliferation rate in cell culture of SKOV-3 cells was higher than of 
SKBR-3 cells [39] while it was opposite for tumor xenografts. Absorbed radiation dose rate to 
the ovarian tumors was lower than breast after 227Th-trastuzumab, which fits well with the in 
vitro studies described above. This low dose rate could be due to weaker expression of HER2 
because this leads to fewer binding sites available for 227Th-trastuzumab binding. The growth 
inhibitory effect of 200 kBq/kg 227Th-rituximab against mice with Raji, NHL xenografts [37] 
was better than for 200 kBq/kg 227Th-trastuzumab. However, higher dosages 227Th-trastuzumab 
demonstrated relatively better anti-tumor effects than higher dosages of 227Th-rituximab (Table 
2). Tumor growth delay after administration of higher dosages 227Th-trastuzumab was superior 
as compared to the higher dosages of 227Th-rituximab. This difference might be due to the 
variation in the optimal dose delivery to tumors which may be achieved at higher dosages for 
227Th-trastuzumab and at lower dosages for 227Th-rituximab. 227Th-RIT resulted in transient 
decrease of white blood cells (Table 2). The extent of white blood cell reduction increased with 
increasing dosage of 227Th-trastuzumab. Therapeutic effects of 400 kBq/kg 227Th-trastuzumab 
was also considerably good. Therefore, we consider that the optimal therapeutic effects, i.e. low 
toxicity and good treatment efficacy, was achieved with 400 kBq/kg of 227Th-trastuzumab.  
 
 
 
 
43 
 
Table 2: Summary of therapeutic and toxic effects of 227Th-RICs 
 
 
N.E: Not estimated  
7.2 Treatment of mice with breast cancer and ovarian cancer 
xenografts with 177Lu-trastuzumab 
Administration of 200 MBq/kg 177Lu-trastuzumab resulted in growth inhibition of breast 
carcinomas with improvement in survival. Lower dosages of 177Lu-trastuzumab (40 MBq/kg vs 
breast and 72 MBq/kg vs ovarian) failed to exhibit anti-tumor effects. Slightly higher dosage 
(74 MBq/kg) of 177Lu-d9MAb used for treatment of mice with intraperitoneal gastric carcinoma 
cells (HSC45-M2) improved the survival (Table 3) [104]. In previous studies, the dosages 
between 200 – 296 MBq/kg were reported to be the lowest dosages used for both 177Lu-
pertuzumab and 177Lu-trastuzumab in HER2 positive ovarian and breast carcinoma, 
227Th-trastuzumab against breast carcinomas 
Tumor dose (injected 
activity) 
                 Delay to grow to a volume of  
 500 mm3                                1000 mm3 
Toxicity (WBC count) 
1.5 Gy (200 kBq/kg) 4 days 9 days Reversible decrease upto 5 
weeks 
3 Gy (400 kBq/kg) 23 days 46 days Reversible decrease upto 5 
weeks 
4.5 Gy (600 kBq/kg) 45 days 57 days Reversible decrease upto 9 
weeks 
7.5 Gy (1000 kBq/kg) 38 days 170 days Reversible decrease upto 9 
weeks 
227Th-trastuzumab against ovarian carcinomas 
2 Gy (200 kBq/kg) 0 days 0 days No 
4 Gy (400 kBq/kg) 8 days 27 days Reversible decrease upto 6 
week 
6 Gy (600 kBq/kg) 30 days 34 days Reversible decrease upto 6 
week 
227Th-rituximab against Non-Hodgkin’s lymphoma 
2 Gy (200 kBq/kg) N.E 17 days Reversible decrease upto 4 
weeks 
4 Gy (400 kBq/kg) N.E 15 days Reversible decrease upto 7 
weeks 
10 Gy (1000 kBq/kg) N.E 40 days Reversible decrease upto 9 
weeks  
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respectively [41, 42]. It seems like the dosages used for the ovarian cancer model in this study 
were too low. 
 
Table 3: Summary of therapeutic and toxic effects of 177Lu-RICs 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
N.E= Not estimated  
I.P = Intraperitoneal administration  
 
177Lu-trastuzumab against breast carcinomas 
Tumor dose 
(injected activity) 
                 Delay to 
grow to a volume of  
 500 mm3                 
Survival  Toxicity (WBC 
count) 
3 Gy (40 MBq/kg) 1 day Failed to improve No seen 
16 Gy (200 
MBq/kg) 
74 days Significantly 
Improved  
Reversible decrease 
upto 5 weeks 
177Lu-trastuzumab against ovarian carcinomas 
4 Gy (72 MBq/kg) -5 days Failed to improve No seen 
177Lu-pertuzumab against ovarian carcinomas 
32 Gy (200 
MBq/kg) 
75 days Significantly 
Improved 
N.E 
50 Gy (280 
MBq/kg) 
> 90 days Significantly 
Improved  
N.E 
177Lu-d9MAb against gastric carcinoma (I.P) 
(74 MBq/kg) N.E Significantly 
Improved (> 200 
days) 
 Reversible decrease 
upto 5 weeks 
(296 MBq/kg) N.E Significantly 
Improved (> 200 
days) 
Reversible decrease 
upto 6weeks 
(592 MBq/kg) N.E Significantly 
Improved (> 200 
days) 
Reversible decrease 
upto 6 weeks 
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7.3 Comparison of 227Th-trastuzumab and 177Lu-trastuzumab in the 
breast cancer xenograft model 
At the same therapeutic level (100 % prolonged growth delay as compared to control) the  
absorbed radiation dose of 227Th-trastuzumab to the tumor was 3 times lower than for 177Lu-
trastuzumab. In other words, 227Th-trastuzumab was 3 times more efficacious than 177Lu-
trastuzumab. In our previous study on NHL tumor xenografts, RBE of 227Th-rituximab was 
between 2.5 and 7.2 and showed that administration of low dose 227Th-rituximab was more 
effective per dose unit as compared to both low LET RIT (Zevalin) and X-radiation [38]. Using 
similar end point, RBE of 211At-MX35 f (ab) 2 was found to be 3.6 - 6.3 compared to external 
radiation (60Co)  in ovarian cancers [105]. In targeted therapy, end-points for RBE are efficacy 
or toxicity, for such end points, the RBE is in the range of 3 to 7 [24]. Thus, RBE for treatment 
of tumors with 227Th-trastuzumab was almost similar to RBE of 227Th-rituximab and of 211At-
MX35 f (ab) 2.  
In contrast, at similar toxicity level (reversible 50 % decreased of WBC count), the 
increase in growth delay was 3 times longer with 177Lu-trastuzumab than for 227Th-trastuzumab 
which indicates that therapeutic index of 177Lu-trastuzumab was superior to the 227Th-
trastuzumab. In tumor tissue, the absorbed radiation dose rate was lower for 227Th-trastuzumab 
than for 177Lu-trastuzumab. This difference may indicate that 177Lu-trastuzumab is suitable for 
more rapidly growing tumors than 227Th-trastuzumab. This may partly explain the difference in 
the therapeutic index. However, small sized metastatic spots in humans are more suitable for 
short range alpha than long range beta emitters. Therefore, it can be anticipated that therapeutic 
index would have been higher for 227Th-trastuzumab than for 177Lu-trastuzumab in clinical 
condition.  
7.4 Comparison of 227Th-trastuzumab and 177Lu-trastuzumab in the 
ovarian cancer xenograft model. 
The difference in the therapeutic efficacy of 227Th-trastuzumab and 177Lu-trastuzumab was 
determined at similar absorbed radiation dose to tumor. An absorbed radiation dose of 4 Gy in 
SKOV-3 tumor was achieved after 400 kBq/kg 227Th-trastuzumab and 72 MBq/kg 177Lu-
trastuzumab. Therapeutic efficacy of 227Th-trastuzumab (tumor growth inhibition and improved 
survival) was superior to 177Lu-trastuzumab. In addition, normal organ toxicity was not seen 
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with 177Lu-trastuzumab.The reason of the failure of 177Lu-trastuzumab could be that the 
administered dose was too low to produce any effect, or inherently radioresistent behavior of 
ovarian tumors, as mentioned above. Administration of 200 MBq/kg 177Lu-pertuzumab 
demonstrated anti-tumor effects against ovarian carcinomas [41]. Higher doses of 177Lu-
trastuzumab might have shown relatively better anti-tumor effects against ovarian cancers and 
should be tested in the same tumor model. 
7.5 The 223Ra daughter nuclide 
Biodistribution experiments showed that 223Ra was excreted either through intestine or ends up 
in the bone as hydroxyapatite crystals. Microautoradiography studies of 227Th-rituximab have 
also indicated that 223Ra and its daughters contribute to the absorbed radiation dose to the bone 
marrow [33]. Bone distribution of 223Ra has also been reported in other studies [106]. Radium-
223 has considerably longer half life (11.4 days) than its daughters (milliseconds to minutes). 
Therefore, absorbed radiation dose contribution of 223Ra daughters was considered to occur as 
the same site as 223Ra. One could suspect that uptake of 223Ra distribution can lead to serious 
consequences. In the present studies, however, 223Ra related effect appeared to be mild and 
short term due to no effect on platelets (remained unaffected). In addition, clinical studies have 
also shown how well the 223Ra is tolerated without exerting serious toxic effects on bone 
marrow [106-109]. Low bone marrow toxic effects of 223Ra could be due to its decreased 
localization to bone which could be caused by; 1) 1ong half-life of 227Th may allow excretion 
of larger amount of 227Th-trastuzumab before the 223Ra is generated, 2) 223Ra generated inside 
cells due to internalization of 227Th-trastuzumab after binding to the HER2, resulting in 
decreased free 223Ra, as mentioned above. In addition, the short range of alpha particles emitted 
by 223Ra could be a potential reason for the low toxicity as shown previously [106]. Therefore, 
in the present study the role of 223Ra may add a therapeutic effect with minimal toxicity, 
showing no worries for the selection of 227Th in RIT.  
7.6 Internalization of the radioimmunoconjugate 
Target antigen internalization from cell surface after antibody binding is an important 
contributing factor in RIT [110]. HER2 antigen internalization after binding to227Th-
trastuzumab traps 227Th–trastuzumab inside the cell and therefore some of the 223Ra forms 
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inside the cell and thereby possibly contributed to total tumor absorbed dose instead of being 
taken up in bone. It has been shown that 50 to 75 % of total absorbed dose came from 
internalized activity after 227Th-trastuzumab [39]. Internalization of 227Th –trastuzumab could 
also result in a close proximity between the point of decay and the cell nucleus compared with 
decays from radionuclides at cell surface and thus a higher probability of hitting the nucleus 
with the alpha particle. Thus, trastuzumab internalization probably contributed to anti-tumor 
effects and low toxicity seen after both RICs. 
7.7 Size of tumor vs range of alpha and beta particles 
Tumor size is an important determinant for the choice of radionuclides [111]. The size of tumor 
xenografts used in this study was considerably larger (4-8 mm) than actual metastases (< 2 mm) 
and may be more ideal for beta particles than alpha particles. Therefore, higher doses (16 Gy) 
of long range (0.67 mm) 177Lu-trastuzumab demonstrated considerable therapeutic effects. On 
comparison with alpha particle, anti-tumor effect caused by short ranged 227Th- in this tumor 
model (solid, large and radioresistent tumors) is quite encouraging. Although, 227Th- is able to 
deliver a tremendous amount of energy in a very short range, the probability to hit the cells in 
this tumor model was lower due to physical and physiological limitations, including short 
range, stochastic nature of alpha radiation, long half life vs growth rate of tumors, 
inhomogeneous HER2 distribution and tumor microvasculature. Therefore, this shows that the 
targeted delivery or internalization of 227Th-trastuzumab may not only be the reason for growth 
inhibitory effects and some other mechanisms might have involved. Autoradiography images of 
227Th-trastuzumab have shown hot spots in perfused areas within the tumor indicating the 
destruction of blood vessels (paper 1). Lack of nutrient due to tumor vasculature destruction by 
high LET alpha particle 227Th or 223Ra could be a reason. It has also been shown that a positive 
therapeutic effect could be expected by targeting solid tumor vasculature with alpha particle 
emitting radionuclide therapy [112, 113]. Therefore, we assume that good therapeutic effects of 
227Th-trastuzumab in our model is due to combined effect of 227Th-trastuzumab, internalization 
of HER2 after binding to trastuzumab, 223Ra and destruction of blood vessels. 
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7.8 Therapeutic and toxic effect of non-targeted 227Th-rituximab 
Absorbed radiation dose to the tumor was higher compared to normal organs after injections of 
227Th-trastuzumab and 177Lu-trastuzumab but not for non-targeted 227Th-rituximab. 
Administration of different dosages of non-targeted 227Th-rituximab, neither inhibited tumor 
growth nor improved the survival of mice with HER2 positive tumors. This emphasizes the 
importance of antibody binding to specific target antigen to achieve desired antitumor effects. 
Normal organ toxicity was not measured after 227Th-rituximab treatment. 
7.9 Therapeutic and toxic effect of trastuzumab 
 In the present study, trastuzumab therapy alone neither inhibited growth of HER-2 expressing 
carcinomas (SKBR-3 and SKOV-3) nor improved the survival. The administered doses were 
similar that is used in clinics (paper 1) [7]. The reason of this failure could be partly explained 
by the absence of immune mediated tumor cell killing in immunodefficient mice [114]. 
Moreover, as there is reduced vascularity and blood flow at the center of growing tumor, 
trastuzumab might not have reached or bound to all receptors [115]. However, when we labeled 
trastuzumab with 227Th or 177Lu, it demonstrated anti-tumor effects. Therefore, we believe that 
the clinical effects of trastuzumab can be enhanced when labelled with 227Th-or 177Lu. 
7.10  Normal tissue toxicity  
Normal tissue functions (liver, kidney and bone marrow) remained intact after administration of 
both RICs. Maximum tolerated activity reflects the tolerability of whole body functions after 
treatment. For 227Th-conjugates maximum tolerated activity was 1000 kBq/kg (Table 2). In 
comparison to 225Ac-conjugates (a radionuclide with long half life) [28] maximum tolerated 
activity was higher for 227Th-trastuzumab than for 225Ac-conjugates [116-118]. The reason for 
the lower MTA for 225Ac-conjugates could be probably short half life of daughter nuclide of 
225Ac which produce higher immediate activity [28]. For 177Lu-conjugates, maximum tolerated 
activity of 1000 MBq/kg of 177Lu-1033-BR96 has been reported [119].  
Although bone marrow toxicity is generally the dose limiting factor in RICs testing, 
renal toxicity has been also observed for 225Ac and 213 Bi [28]. A transient decrease of WBC 
count was seen in first few weeks after the administration of highest dosages of 227Th-
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trastuzumab, which may partly was due to bone-relocalization of 223Ra. Similar results were 
observed after 227Th-rituximab in mice bearing NHL tumor [37] (Table 2). Maximum tolerated 
dose to the bone marrow was more than 2.1 Gy for 227Th-rituximab [28]. Dosimetry methods 
used in preclinical studies to determine the maximum tolerated dose were different from each 
other and therefore also difficult to compare different treatment groups [28].  
7.11  Conclusion 
 Regulatory authorities usually require toxicity data from at least one species before allowing 
studies in humans with a radiopharmaceutical. Administration of 227Th-RICs, both in the 
present and previous studies, showed considerably good therapeutic effects with very low 
toxicity. Therefore, we believe that this radionuclide (227Th) has a potential to be tested in 
clinics in patients with micrometastatic disease. While, low LET emitting 177Lu-trastuzumab 
has also showed treatment potential at high dose. This shows that 177Lu-trastuzumab needs 
more preclinical evaluations, including determination of maximum tolerated dose (MTD), in 
both solid (HER2 expressing tumors) and haematological tumors. 
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8 Conclusions and future prospects 
8.1 Conclusions 
 
1. Administration of high LET 227Th-labeled and low LET 177Lu-labeled trastuzumab was safe 
at the activity concentrations used. 
2. 227Th-trastuzumab inhibited growth of HER2 expressing carcinomas in a dose dependent 
manner and improved survival of treated mice. 
3. RBE of 227Th-trastuzumab was superior to 177Lu-trastuzumab when compared at relatively 
low radiation dose to the tumor. 
4. Therapeutic index of 177Lu-trastuzumab was superior to that of 227Th-trastuzumab. 
5. A transient decrease of white blood cells (WBC) was the only toxicity observed with 
administration of higher dosages of both RICs except 1000 kBq/kg of 227Th-trastuzumab where 
weight loss was also observed in few animals. 
 
8.2 Future prospects 
 
1. Comparison of 227Th-trastuzumab and 177Lu-trastuzumab in micrometastases or 
intraperitoneal mouse model can be started. In addition, maximum tolerated doses (MTD) 
should be determined for both RICs.  
2. Xenografts sizes used were much larger than the size of the micrometastases in breast and 
ovarian cancer patients. Therefore, we suggest testing 227Th-trastuzumab as an adjuvant 
treatment in breast and ovarian cancers patients with micrometastases. 
3. Clinical trails of 227Th-RICs in patients with a high risk of developing bone metastasis 
warrant further studies, due to 223Ra affinity to bone. 
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Experimental a-particle radioimmunotherapy of
breast cancer using 227Th-labeled p-benzyl-DOTA-
trastuzumab
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Abstract
Background: The aim of the present study was to explore the biodistribution, normal tissue toxicity, and
therapeutic efficacy of the internalizing low-dose rate alpha-particle-emitting radioimmunoconjugate
227Th-trastuzumab in mice with HER2-expressing breast cancer xenografts.
Methods: Biodistribution of 227Th-trastuzumab and 227Th-rituximab in nude mice bearing SKBR-3 xenografts were
determined at different time points after injection. Tumor growth was measured after administration of 227Th-
trastuzumab, 227Th-rituximab, cold trastuzumab, and saline. The toxicity of 227Th-trastuzumab was evaluated by
measurements of body weight, blood cell, and clinical chemistry parameters, as well as histological examination of
tissue specimens.
Results: The tumor uptake reached peak levels of 34% ID/g (4.6 kBq/g) 3 days after injection of 400 kBq/kg of
227Th-trastuzumab. The absorbed radiation dose to tumor was 2.9 Gy, while it was 2.4 Gy to femur due to uptake
of the daughter nuclide 223Ra in bone; the latter already explored in clinical phases I and II trials without serious
toxicity. A significant dose-dependent antitumor effect was observed for dosages of 200, 400, and 600 kBq/kg of
227Th-trastuzumab but no effect of 400 and 600 kBq/kg 227Th-rituximab (non-tumor binding). No serious delayed
bone marrow or normal organ toxicity was observed, but there was a statistical significant reduction in blood cell
parameters for the highest-dose group of 227Th-trastuzumab treatment.
Conclusion: Internalizing 227Th-trastuzumab therapy was well tolerated and resulted in a dose-dependent
inhibition of breast cancer xenograft growth. These results warrant further preclinical studies aiming at a clinical
trial in breast cancer patients with metastases to bone.
Keywords: alpha radiation, radioimmunotherapy, SKBR-3, trastuzumab, thorium-227
Background
Metastatic breast cancer patients have poor prognosis
despite recent therapeutic advances [1]. The human epi-
dermal growth factor receptor-2 (HER-2/neu) is a trans-
membrane receptor tyrosine kinase that is over-expressed
in 25% to 30% of metastatic breast cancers and associated
with more aggressive disease [2]. Trastuzumab (Hercep-
tin®) is a humanized monoclonal antibody (mAb) directed
against this antigen and shows clinical activity in women
both with HER2/neu-overexpressing primary and meta-
static breast cancer [3].
Tumor cell-targeted alpha emitters have the potential
to improve therapy of hematological malignancies and
micrometastatic disease. Alpha particles have a short
path length (50 to 80 μm) and high linear energy transfer
(LET approximately 100 keV/μm) and, thus, deliver a
high amount of DNA-damaging energy to cells in close
vicinity of their decay. However, no alpha-emitting radio-
immunoconjugate (RIC) has reached phase III clinical
trial yet due to poor physical or chemical characteristics,
supply limitations, and high production costs for the
most promising alpha emitters [4]. Recently, we have
suggested 227Th as a novel radionuclide for alpha-particle
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radioimmunotherapy (RIT), as this radionuclide can be
produced in clinically relevant amounts from b-decay of
the long-term generator 227Ac [5,6]. 227Ac can be pro-
duced by thermal neutron irradiation of 226Ra in a
nuclear reactor. The yield of 227Ac after purification is
relatively high and 226Ra is highly available, making the
process cost efficient. 227Ac has a half-life of 21.8 years
and thus, would serve as a generator nuclide for 227Th
production for decades [7].
Thorium-227 decays via its alpha- and beta-emitting
daughters 223Ra, 219Rn, 215Po, 211Pb, 211Bi, and 207Tl to
stable 207 Pb. The long half-life of 227Th (T1/2 = 18.7
days) permits the tumor targeting and normal tissue
clearance of a 227Th-labeled RIC to occur before larger
amounts of the daughter nuclide 223Ra is generated.
Upon decay, 223Ra will detach from the antibody. Impor-
tantly, clinical trials have not shown worrisome toxicity
of 223Ra injected as a therapy for prostate cancer bone
metastases [8,9]. Previously, we have shown that 227Th
conjugated to the monoclonal antibody rituximab was
effective in treatment of mice with lymphoma xenografts
and had a relatively low normal tissue toxicity [7,10,11].
The conjugation of trastuzumab with different alpha-
particle-emitting radionuclides, i.e., 211At, 225Ac, and
213Bi, has already been investigated by other groups
[12-16]. The purpose of the present study was to deter-
mine the biodistribution, therapeutic effect, and toxicity
of the low-dose rate alpha-particle-emitting RIC 227Th-
trastuzumab on HER2-expressing SKBR-3 xenografts. In
vitro experiments have shown internalization of the
227Th-trastuzumab/HER2 complex, retention of 227Th,
and a high toxic effect against single tumor cells [17].
The increased cytotoxic effect created by alpha particles
may offer the opportunity to both improve the overall
response rate of the trastuzumab treatment and also to
treat patients with a lower HER2 expression.
Material and methods
Production of 227Th and radiolabeling of monoclonal
antibodies
227Ac was produced through thermal neutron irradiation
of 226Ra followed by b- decay of 227Ra (T1/2 = 42.2 min)
to 227Ac [18]. 227Th was selectively retained from a
227Ac decay mixture in 7 M HNO3 by anion exchange
chromatography [19].
Radiolabeling of trastuzumab (Herceptin®, Hoffmann-
La Roche, Basel, Switzerland) and rituximab (MabThera,
Hoffmann-La Roche) with 227Th was performed at Algeta
ASA, Oslo, Norway. The antibodies were conjugated with
p-SCN-Bn-DOTA at pH 9 (sodium borate buffer) at 37°C
over night. The number of DOTA molecules per anti-
body was approximately four as determined by LC/MS
analysis. The conjugate was purified with a spin filter
(Amicon, Millipore, USA) using 0.9% NaCl as running
buffer removing daughter nuclides and non-chelated
227Th. The purified antibody was distributed to micro-
centrifuge tubes (1 mg/tube) and freeze dried to keep a
larger batch under stable conditions over a long period of
time. The freeze-dried conjugate was dissolved in sodium
acetate buffer pH 5.5 and added about 4 MBq of newly
purified 227Th in 0.01 M HCl. The reaction was done
over night at 42°C in a thermomixer (Eppendorf, Ham-
burg, Germany). The chelate was purified on a NAP5 col-
umn (GE Healthcare, Little Chalfont, UK) using PBS as
running buffer. The specific activity was 1000-1600 kBq/
mg with regard to 227Th.
Immunoreactivity
The immunoreactive fraction (IRF) of the radioimmuno-
conjugate 227Th-trastuzumab was estimated by measur-
ing the cell bound activity in a one point assay. SKOV-3
cells (2 × 107 cells/ml) in 200 μl PBS were used. Four
million SKOV-3 cells in one vial of cells were blocked by
incubating with 150 μg/ml cold trastuzumab for 15 min
at 37°C. The cells in another vial were not blocked.
About 500 cpm of 227Th-trastuzumab was added to each
vial and the cells were incubated for 2 h before washing
and measurement of radioactivity with an automated
gamma counter (Wizard, Packard Instrument Co., Down-
ers Grove, IL, USA). IRF was 70% to 90%.
Animals
All procedures and experiments involving animals in this
study were approved by the National Animal Research
Authority and carried out according to the European Con-
vention for the Protection of Vertebrates used for Scienti-
fic Purposes. The animals were maintained under
pathogen-free conditions. Food and water were supplied
ad libitum. Eight to 12 weeks old, institutionally bred
female Balb/C nu/nu (NCR) mice, with an average weight
of 20 to 27 g at the start of study, were used. Mice were
anesthetized with subcutaneous injection of 0.05 ml Zole-
til® mix (Virbac, Carros Cedex, France) before HER-2-
positive breast cancer (SKBR-3) tumor fragments from
xenografted animals (1 × 1 × 1 mm) were implanted
subcutaneously. The xenografted tumor line originated
from HER-2-positive breast cancer (SKBR-3) cells from
American Type Culture Collection (Manassas, VA). Mice
with growing tumors of diameters between 4 and 8 mm
were included in the experiments. Mice were killed by cer-
vical dislocation.
Biodistribution of 227Th-labeled antibodies
The conjugates 227Th-trastuzumab and 227Th-rituximab
were administered by tail vein injection of 100 μl (15 kBq)
solution to each animal. For each conjugate and time
point, a total of four to six animals were autopsied. Tumor
and organs were measured for radioactivity content and
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weighed. Samples of the injectates (10%) were used as
references in the measurement procedure.
Thorium-227 and 223Ra were measured using a solid-
state photon well detector (GCW6021, Canberra, Meridan,
CT, USA) coupled to a digital gamma ray spectrometer
and analyzed using the computer software Apex™ version
1 (Canberra). For 227Th, the 236 keV (abundance 17.6%)
and 256 keV (abundance 9.5%) g-ray lines were used and
for 223Ra the 154 keV (abundance 5.7%), 269 keV (abun-
dance 13.9%), 324 keV (abundance 4%), and 338 keV
(abundance 2.8%) g-ray lines were used.
Calculation of absorbed dose
The total number of disintegrations, i.e., the cumulated
activity, in various tissues from the time of injection of
the preparation until no activity was left in the body was
estimated by calculation of the area under the activity
concentration versus time curves (AUC). For 227Th-
labeled antibodies, the absorbed radiation doses were cal-
culated assuming dose contributions coming only from
a-particle emissions with a mean a-energy (Ea) of 5.9
MeV for 227Th and 26.4 MeV for 223Ra with its daughters
in equilibrium, and that there was a 100% absorption of
the absorbed dose from the a-particle within a tissue, i.e.,
absorbed fraction equal to unity (ø = 1). For a-particle
radiation uniform distribution of radionuclides in the
various tissues as well as no cross irradiation was
assumed. Thus, the total absorbed dose to each organ
was estimated by: Dose = AUC0
∞ · Ea (
227Th) + AUC0
∞ ·
Ea (
223Ra + daughters). Also for blood, the absorbed dose
was calculated assuming 100% absorption of the a-parti-
cles, i.e., ø = 1. This was obviously a simplification since
in the capillaries there will probably be escape of a-parti-
cles beyond the blood.
Therapeutic studies
Mice were injected with a single dose of NaCl (control;
n = 10), 20 μg (n = 5), 100 μg (n = 6), or 250 μg (n = 5)
of cold trastuzumab; 200 kBq/kg (n = 10), 400 kBq/kg (n
= 11), and 600 kBq/kg (n = 12) of 227Th-trastuzumab;
and 400 kBq/kg (n = 9) and 600 kBq/kg (n = 10) 227Th-
rituximab in 100 μl solution. Tumor growth and mouse
weight were assessed three times a week in the first week
before injection and the 3 weeks after injection; there-
after, weight, growth, and survival were assessed twice a
week. Caliper measurements of perpendicular tumor dia-
meters were used to estimate tumor volume by assuming
ellipsoid shape. Mice with tumor diameter larger than
20 mm were killed. Mantley Cox log rank test was used
to test for significant differences in surviving fraction of
mice, which is defined as the fraction of mice that did
not have to be sacrificed due to tumor diameter above
20 mm.
Evaluation of toxicity
Toxicity was evaluated in all treatment groups except
227Th-rituximab. Approximately 100 to 200 μl of blood
was collected from the vena saphena lateralis in 500 μl
EDTA-coated tubes (Microtainer K2E tubes, Becton,
Dickinson, NJ, USA) for blood cell counting. Blood sam-
ples were taken before and at 3, 6, and 8 to 10 weeks after
start of the study. For control, a group of ten mice without
tumor was injected with NaCl and sampled at the same
time points for blood cell count. While for clinical chemis-
try data, the samples from this control group were taken
after 8 weeks. Blood cells were counted in an automatic
blood counter (Scil Vet ABC, Horiba ABX, Montpellier,
France). In addition, when mice were sacrificed due to
tumor size or weight loss, blood samples were collected by
heart puncture into EDTA-coated tubes and also lithium
heparin-coated tubes (Microtainer LH tubes, Becton,
Dickinson) for analysis of clinical chemistry parameters.
Clinical chemistry strips were used to assess the serum
aspartate aminotransferase (AST), alanine aminotransfer-
ase (ALT), alkaline phosphatase (ALP), and urea level
(Reflotron, Roche Diagnostics GmbH, Mannheim,
Germany). Full blood samples (30 μl) were analyzed by a
clinical chemistry analyzer (Reflovet, Roche Diagnostics).
At the end of the study, the lung, heart, kidney, spleen,
small intestine, large intestine, liver, femur, skull, and
tumor were fixed with formalin, cut in 5-μm slices, stained
with hematoxylin and eosin, and analyzed by a pathologist
to detect any pathological changes. Slides from cold trastu-
zumab and 227Th-trastuzumab groups were compared to
the slides of control groups.
Autoradiography
Mice bearing tumor xenografts were injected with 15 kBq
of 227Th-trastuzumab, corresponding to approximately
600 kBq/kg. Four animals were sacrificed by cervical
dislocation 4 and 8 days after injection. Tumors were
removed and immediately frozen in liquid nitrogen.
Tissue sections of thickness 5 μm were used for exposure
of Kodak Biomax MR-1 single-sided emulsion or Kodak
Medical General Purpose Blue x-ray film (Eastman
Kodak Company, Rochester, NY, USA). Films were
exposed for 6 to 11 days at -80°C prior to development.
Film patterns were compared to hematoxylin and eosin
(H/E)-stained tissue sections.
Results
Biodistribution and dosimetry of 227Th -trastuzumab and
227Th-rituximab
The in vivo biodistribution profiles of 227Th-trastuzu-
mab, 227Th-rituximab, and the daughter nuclide 223Ra in
nude mice with SKBR-3 xenografts at different time
points after administration are shown in Figure 1. The
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maximum uptake of 227Th-trastuzumab in tumor
(4.6 kBq/g) occurred 3 days after injection (Figure 1a).
There was a large difference between the amount of
activity in tumor and in normal organs for 227Th-trastu-
zumab. The uptake of non-tumor binding 227Th-rituxi-
mab (Figure 1b) in tumor was significantly lower than
the uptake of 227Th-trastuzumab (Figure 1a). The 227Th
daughter nuclide 223Ra was mainly localized to bone
(femur and skull) but there were also some retention of
223Ra in spleen, kidneys, and in tumor (Figure 1c, d).
The absorbed radiation dose in tumor was 2.9 ± 0.8 Gy
for 227Th-trastuzumab (Figure 2a) and 0.7 ± 0.1 Gy for
227Th-rituximab (Figure 2b); both normalized to injections
of 400 kBq/kg. Radiation doses were less than 2 Gy for all
organs for both RICs, except for femur (2.4 ± 0.6 Gy) and
skull (2.7 ± 0.6 Gy) in mice treated with 227Th-trastuzumab.
Therapeutic efficacy
Growth of SKBR-3 tumor xenografts in mice treated
with alpha-particle-emitting 227Th-trastuzumab was
compared with cold trastuzumab, non-tumor binding
227Th-rituximab, as well as saline (controls; Figure 3).
There was a large variability in tumor growth within
treatment groups. Table 1 shows growth delays calcu-
lated from average tumor growth curves. The mean
tumor growth in mice treated with cold trastuzumab
(20, 100, and 250 μg/mice or approximately 0.8, 4, and
10 mg/kg body weight) or 400 and 600 kBq/kg 227Th-
rituximab was similar to the growth of the untreated
controls. The dosage groups for cold trastuzumab and
for 227Th-rituximab in Table 1 and Figure 3b, c were
pooled since there was no difference between them. For
200 and 400 kBq/kg 227Th-trastuzumab, some of the
tumors responded well to the treatment, while others
did not (Figure 3d, e). The average delays to grow to a
normalized tumor volume of 500 mm3 were 7 and
23 days, respectively (Table 1). For 600 kBq/kg 227Th-
trastuzumab, all tumors responded to the treatment
(Figure 3f) and the average growth delay to reach a
tumor volume of 500 mm3 was 45 days (Table 1).
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Figure 1 Biodistribution of 227Th-conjugates and 223Ra in mice with SKBR-3 xenografts. Biodistribution profile of 227Th-trastuzumab (a) and
daughter nuclide 223 Ra (c) after administration of 227Th-trastuzumab, and biodistribution of 227Th-rituximab (b) and daughter nuclide 223 Ra (d)
after administration 227Th-rituximab, in mice bearing SKBR-3 xenografts. The measured 227Th activities were normalized to an injection of 400
kBq/kg bodyweight. Values are mean ± SD. N = 6 for each time point except at day 3, where N = 5.
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The surviving fraction of the different dosages of 227Th-
trastuzumab was not significantly different from each
other (p > 0.05), but there was a significant difference in
survival between the 227Th-trastuzumab treatment groups
and control groups (NaCl and trastuzumab; p < 0.001)
(Figure 4a). Mean and median survival times were signifi-
cantly different for mice in the dosage groups 400 and
600 kBq/kg 227Th-trastuzumab as compared to mice in
the NaCl (control) group (p < 0.05; Table 2). None of the
dosages of cold trastuzumab had an effect on survival (p =
0.40). Hence, the data were pooled into one group. The
survival of mice treated with non-tumor-binding 227Th-
rituximab was not significantly different from the survival
of the control group (p > 0. 6; Figure 4b). In addition, no
significant differences (p > 0.05) in mean and median sur-
vival times between control and 227Th-rituximab treat-
ment groups were observed (Table 2).
Toxicity of 227Th-trastuzumab
White blood cell (WBC), platelet cell (PLT) counts, and
clinical chemistry parameters of control mice and mice
treated with 227Th-trastuzumab are shown in Figures 5
and 6. Figure 5a, b shows WBC and PLT counts of indivi-
dual mice as well as mean values at 0, 3, 6, and 9 weeks
time points from each treatment groups. In the control
groups mice without tumor was also included in order to
get measurements at longer follow-up. The WBC count
was significantly lower in the control (NaCl) group at
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Figure 2 Absorbed radiation doses to normal tissues and tumor xenografts. Absorbed radiation dose in tumor and normal organs of mice
injected with 227Th-trastuzumab (a) or 227Th-rituximab (b). Cumulated activities were calculated from biodistribution curves and multiplied with
the mean energy of a-particles from 227Th, 223Ra, and daughters. Biodistribution data of 227Th-trastuzumab and 227 Th-rituximab were normalized
to 400 kBq/kg bodyweight.
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time 0 as compared to 3 weeks after injection. WBC
decreased significantly for treatment with 400 kBq/kg (p
< 0.001, t test) and 600 kBq/kg (p < 0.001, t test) of
227Th-trastuzumab as compared to WBC in the cold tras-
tuzumab group and control mice after 3 weeks (Figure
5a) but not as compared with the 0 time point. After 6
weeks, only the 600 kBq/kg 227Th-trastuzumab group
was significantly different from control (p = 0.008, t test).
No significant difference in PLT count was found for
the 200 kBq/kg 227Th-trastuzumab treatment group
when compared to control at any time point (Figure 5b).
The PLT count was significantly lower for the 400 kBq/
kg (p = 0.017, t test) and 600 kBq/kg (p = 0.003, t test)
227Th-trastuzumab treatments as compared to control
after 3 weeks. At 6 weeks, the PLT counts had recovered.
However, at 9 weeks, the PLT count was significantly
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Figure 3 Effects of 227Th-based RIT on growth of individual SKBR-3 tumor xenografts. Individual tumor growth after treatment with NaCl
(a); 20, 100, and 250 μg cold trastuzumab (b); 227Th-rituximab at dosage of 400 and 600 kBq/kg (c); 200 kBq/kg (d); 400 kBq/kg (e) and 600 kBq/
kg (f) of 227Th-trastuzumab. N = 9 to 19.
Table 1 Growth inhibition for tumor volume of 500 and 1,000 mm3 after treatment
Treatment Dosage 500 mm3 1,000 mm3
Daysa Growth delayb Days Growth delay
NaCl 15 ± 7 0 ± 10 25 ± 7 0 ± 11
Trastuzumab (pooled) 20 - 250 μg 15 ± 7 0 ± 11 23 ± 8 -2 ± 12
227Th-rituximab 400 and 600 kBq/kg 15 ± 8 -3 ± 11 27 ± 10 2 ± 11
227Th-trastuzumab 200 kBq/kg 22 ± 8 7 ± 11 32 ± 8 7 ± 12
227Th-trastuzumab 400 kBq/kg 38 ± 8 23 ± 10 70 ± 10 45 ± 12
227Th-trastuzumab 600 kBq/kg 60 ± 7 45 ± 7 90 ± 10 65 ± 7
aThe number of days to reach the chosen tumor volume. bGrowth delay = days (treatment) - days (NaCl).
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lower than the control for the 400 kBq/kg 227Th-trastu-
zumab group (p = 0.038, t test) and for the cold trastuzu-
mab group (p < 0.001, t test) as compared to control
mice.
Urea, AST, ALT, and ALP levels in blood from control
mice were compared with blood from mice treated with
cold trastuzumab, 200, 400, and 600 kBq/kg of 227Th-
trastuzumab (Figure 6a, b, c, d). Urea levels were within
the normal range and were not significantly different
from control. One mouse in each RIT group and one
control mouse showed high ALT levels, i.e., above nor-
mal range. Another mouse treated with 200 kBq/kg
227Th-trastuzumab group had a very high AST levels as
compared to mice in all other treatment groups. Large
variations in ALP levels were observed among all treat-
ment groups but were within the normal range. Therapy
related pathological changes were not observed in any
organ upon histological examination.
Figure 7 shows no morphological differences in normal
bone marrow for a mouse treated with NaCl (Figure 7a)
and a mouse treated with 600 kBq/kg of 227Th-
trastuzumab up to 72 days (Figure 7b). Body weights of
animals were measured throughout the study but no sig-
nificant differences between the treatment groups were
observed (data not shown).
Autoradiography
Autoradiography of SKBR-3 tumor xenografts showed
that the distribution patterns of radioactivity after injec-
tion of 600 kBq/kg of 227Th-trastuzumab were inhomo-
geneous (Figure 8). The smallest of the tumors analyzed
showed highest concentration of radioactivity present as
a rim corresponding to areas with viable tumor tissue
close to the well perfused connective tissue capsule sur-
rounding the tumor (Figure 8a). The tumor in Figure 8b
had localized hotspots. On the corresponding H/E-
stained tissue section, the hotspots with high 227Th-tras-
tuzumab uptake matched areas with high density of
blood vessels and/or large blood vessels, with areas of
necrotic tissue and loosely bound cells in between. A
similar correspondence was also seen in tissue sections
taken at later time points (Figures 8c, d).
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Figure 4 Effects of 227Th-based RIT on survival of mice with SKBR-3 tumor xenografts. Survival of mice after intravenous injection of NaCl,
20,100, and 250 μg cold trastuzumab, and 200, 400, and 600 kBq/kg 227Th-trastuzumab (a), or 400 and 600 kBq/kg 227Th-rituximab (b).
Table 2 Mean and median survival times for all treatment groups
Treatment Dosage Mean ± standard error Median ± standard error Number of mice
NaCl 52 ± 10 42 ± 13 10
Trastuzumab (Pooled) 20 - 250 μg 54 ± 5 47 ± 2 16
227Th-rituximab 400 kBq/kg 44 ± 5 49 ± 8 9
227Th- rituximab 600 kBq/kg 47 ± 5 36 ± 3 10
227Th-trastuzumab 200 kBq/kg 39 ± 2 38 ± 2 10
227Th-trastuzumab 400 kBq/kg 87 ± 7* 63 ± 3* 11
227Th-trastuzumab 600 kBq/kg 95 ± 3* 96 ± 3* 12
*Significant difference between control and therapy.
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Discussion
The present study of alpha-particle-emitting 227Th-tras-
tuzumab showed a significant dose-dependent inhibition
of tumor growth of human SKBR-3 breast cancer xeno-
grafts in mice, leading to long-term survival with low
toxicity.
In RIT with 227Th the distribution of free daughter
nuclides also has to be considered, as the daughter nuclide
223Ra detaches from the DOTA-trastuzumab construct
upon alpha-particle emission from 227Th. The biodistribu-
tion study showed that 223Ra re-localized to bone and to
spleen. It should be noticed that the 18.7-day half-life of
227Th allows for excretion of a large fraction of 227Th-
trastuzumab before 223Ra is formed. The uptake in spleen
was probably related to mouse-specific calcification of the
spleen [20]. Radium-223 has a half-life of 11.4 days and is
excreted from the blood via the intestines with a major
part of the 223Ra ending up in the hydroxyapatite of bone
[8,20,21]. The half-lives of the 223Ra-daughters are in the
millisecond to minute range. They are therefore likely to
contribute mainly to the absorbed radiation dose in
the vicinity of the site of 223Ra decay. Thus, as shown in
Figure 2 the absorbed doses to bone were comparable to
the doses in tumor.
Microautoradiography studies of 227Th-rituximab have
shown that there probably is a contribution to the bone
marrow absorbed dose from 223Ra and daughters on the
bone surface [11]. One could suspect that localization in
bone would give a high contribution to bone marrow
toxicity, but clinical studies of 223Ra have shown that it
is well tolerated by breast and prostate cancer patients
[8], with data from repeated dosing suggesting no more
damage on red bone marrow compared to placebo [9].
This lack of toxicity is probably due to the short path
length of alpha emission, as previous data have shown
that the beta-emitter strontium-89 is strikingly more
toxic, although presumably localizing in an identical way
in bone tissue [20]. Therefore, we suggest that localiza-
tion of small amounts of 223Ra in bone tissue would be
acceptable. Furthermore, because of the long half-life of
227Th and internalization of HER-2 antigen after binding
to 227Th- trastuzumab complex much of the 227Th will
be excreted or internalized before 223Ra is formed and
thereby reducing relocalization of 223Ra to bone. We
also suggest that an optimized chelator will reduce the
small amounts of free 227Th, indicated by the present
biodistribution data.
No severe bone marrow toxicity was observed in this
study even when therapeutically effective amounts were
administered. A dosage of 600 kBq/kg of 227Th-rituximab
is equal to an absorbed radiation dose in tumor of
around 1 Gy. One could expect a small therapeutic effect
of this dose since there was a significant therapeutic
effect of 200 kBq/kg (1.45 Gy) of 227Th-trastuzumab.
However, there was no therapeutic effect of even the
highest dosage of 227Th-rituximab, showing that the anti-
body has to bind to the cells to get the emitted alpha par-
ticles close enough to the tumor cell nucleus. This is in
analogy with the lack of bone marrow toxicity, discussed
above, i.e., the low bone marrow toxicity might be due to
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Figure 7 Histological examination of bone marrow after 227Th-trastuzumab therapy. Histological microscopy images of bone marrow in
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the lack of binding of 227Th-trastuzumab or 223Ra to
bone marrow cells.
In the present study, the tumor volumes were 8 to 16
times larger than the size of micrometastases (< 2 mm
in diameter) in breast cancer patients. However, in a
previous study we treated single SKBR-3 cells and
achieved up to two log reduction in clonogenic survival
and growth inhibition [17]. Therefore, one relevant clin-
ical setting for 227Th-trastuzumab might be adjuvant
treatment of breast cancer patients with micrometas-
tases. Due to the 223Ra (daughter) affinity to bone,
patients with a high risk of developing bone metastasis
might be an intriguing application [22,23].
There was a dosage-dependent increase in tumor
growth inhibition but not for survival. This may be
related to individual differences in tumor vascularization
and the presence of necrosis. In the 200 kBq/kg group we
observed a variable therapeutic effect, while in the 400
and 600 kBq/kg groups we got a more prominent and
similar therapeutic effect.
Radiolabeled antibody therapy for solid tumor has been
less successful as compared to hematological tumors. The
A C
B D
Figure 8 Autoradiography images after 227Th-trastuzumab therapy. Autoradiography images of the radioactivity distribution in 5-μm-thick
frozen tissue sections from four different SKBR-3 human tumor xenografts in athymic nude mice following injection of 600 kBq/kg of 227Th-
trastuzumab. Tumors in mages (a) and (b) were resected 4 days post injection, while (c) and (d) were removed 8 days post injection. N = 4.
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reasons are that the solid tumors are generally less sensitive
to radiation and are more difficult to target due to macro-
molecule transport barriers, e.g., vascular supply limitation,
high interstitial pressure, and vascular permeability limita-
tion. Targeted delivery of high LET a-particles after
administration of 227Th-trastuzumab may not be the only
reason behind the successful growth inhibition of SKBR-3
tumor xenografts. The autoradiography images indicated
that 227Th-trastuzumab in some tumors, were located close
to the tumor vasculature. Targeting the tumor vasculature
or vasculature near the tumor cells with a-emitting radio-
nuclides has previously been shown to yield a therapeutic
effect on solid tumors [24,25].
The tumors treated in the present study were much
larger than the range of alpha particles. However, the
autoradiogaphy images indicated hot spots of 227Th-tras-
tuzumab activity in perfused areas within the tumor
xenografts, which might result in destruction of the
blood vessels and eradication of tumors due to lack of
nutrients. Furthermore, there was also some retention of
free 223Ra in tumor. This is a small ion with several a-
emitting daughter radionuclides that might surmount the
macromolecular transport barriers of solid tumors and
result in high LET a-irradiation of tumor cells not
reached by the larger molecule 227Th-trastuzumab. Thus,
the antitumor effect might have been a combined effect
of tumor cell kill by both 227Th-trastuzumab, 223Ra, and
daughters and destruction of the blood vessels that deli-
vers nutrients and oxygen to the tumor cells.
At two samplings, the dosage-dependent decrease in
the WBC count was significantly lower for mice in one
or both of the two highest dosages groups compared to
control mice; both for the 400 and 600 kBq/kg 227Th-
trastuzumab groups at 3 weeks after injection, and for
the 600 kBq/kg227Th-trastuzumab at 6-week time
points. However, the blood values were within the nor-
mal physiological range for nude mice for all dosages of
227Th-trastuzumab. Furthermore, the most striking
change in the WBC count is the increase for the control
group from 0 to 3, 6, and 9 weeks. If the WBC count at
3, 6, and 9 weeks are compared with the WBC count of
the control at 0 weeks there is no significant difference.
The reason for this increase is unknown, but it might be
related to an undetected infection in one cage of the
control mice. Therefore, we conclude that the 227Th-
trastuzumab treatment had no pathological effect on the
WBC count.
There was a dosage-dependent decrease in PLT count
at 3 weeks after injection, but the PLT count had recov-
ered after 6 weeks. At the 9-week time point, the PLT
count was significantly lower than the control for the
400 kBq/kg 227Th-trastuzumab group and the cold tras-
tuzumab group. However, this decrease was probably
related to a combination of biological variation and the
low number of mice in these two groups (5 and 1, respec-
tively). It should also be pointed out that control mice
without tumor xenografts were used in order to get
blood samples for the controls at the later time points.
Liver enzymes and urea levels in the blood did not
show any dose-dependent changes following injection of
227Th-trastuzumab with levels in the highest dosage
group similar to that of control. Other treatment groups
showed random increase or decrease of some enzymes
when compared with control. This may be related to
one mouse within each group with very high value of
the parameter in question. Since there were no dose-
dependent changes and since there were no significant
changes between the control and the 600 kBq/kg group
for any parameters, these changes might be due to other
factors than the 227Th-trastuzumab treatment.
In conclusion, 227Th-trastuzumab inhibits growth of
breast cancer xenografts in a dose-dependent manner.
Possibly due to the longer half-life, single dosing was effi-
cacious; not excluding that improved efficacy might be
obtained with multiple doses, as has been shown clini-
cally with a more short-lived alpha emitter [9]. The lim-
ited toxicity of the treatment was mainly related to
reversible bone marrow depression. Further preclinical
studies of 227Th-trastuzumab involving mice with breast
cancer micrometastases and, if possible, metastasis to
bone are warranted.
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Abstract: 
The aim of the present study was to compare the biodistribution, normal tissue toxicity and 
therapeutic effect of the alpha-particle emitting 227Th-trastuzumab and the beta-particle 
emitting 177Lu-trastuzumab in mice with HER2-expressing SKBR-3 breast cancer xenografts.  
Methods: Biodistributions of the two radioimmunoconjugates were determined at different 
time points after i.v. injection. Inhibition of tumor growth was measured after single injection 
of 227Th-trastuzumab (200, 400, 600 or 1000 kBq/kg), 177Lu-trastuzumab (40 or 200 MBq/kg) 
or saline. The toxicity profiles were compared by measurements of body weight, clinical 
chemistry and hematological parameters, as well as histological examination of tissue 
specimens. 
Results: 400 kBq/kg of 227Th-trastuzumab and 40 MBq/kg of 177Lu-trastuzumab both resulted 
in an absorbed radiation dose to tumor of approximately 3 Gy. A significant anti-tumor effect 
and increase in survival was observed at injected dosages of 400-1000 kBq/kg of 227Th-
trastuzumab and 200 MBq/kg of 177Lu-trastuzumab as compared to the saline control. When 
compared at the same therapeutic effect level (100 % prolonged growth delay as compared to 
control) the absorbed radiation dose of 227Th-trastuzumab was 3 times lower than with 177Lu-
trastuzumab, which indicates that the relative biological effect (RBE) was 2.8 times higher for 
227Th-trastuzumab than for 177Lu-trastuzumab. In contrast, when compared at the same 
temporary decrease of WBC count (50 % decrease in number of white blood cells as 
compared to control), the increase in growth delay was 3 times longer with 177Lu-trastuzumab 
than with 227Th-trastuzumab, which indicate that the therapeutic index was three times higher 
for 177Lu-trastuzumab than for 227Th-trastuzumab. 
Conclusion: In this xenograft model the RBE was higher for 227Th-trastuzumab than for 
177Lu-trastuzumab, while the therapeutic index of 177Lu-trastuzumab was superior to that of 
227Th-trastuzumab. 
3 
 
Introduction:  
Radioimmunotherapy (RIT) with beta particle emitting anti-CD20 90Y-labeled ibritumomab-
tiuxetan, Zevalin® and 131I-labeled tositumomab, Bexxar®, is an approved treatment for non-
Hodgkin lymphoma. However, the use of RIT is still limited, probably due to alternative non-
radioactive therapies, reimbursement issues, high treatment cost and administration 
procedures [1,2]. Treatment related bone marrow toxicity appears to be the dose limiting 
factor for Zevalin and Bexxar [3]. 
The development of alpha-particle emitting RIT has been halted by lack of 
radionuclides with adequate physical and radiobiological properties and high cost for the most 
promising radionuclides [4]. While beta particles deposit only 0.01- 0.1 keV/Pm of energy per 
distance travelled, alpha particles deposit 25-230 keV/μm. The latter are therefore suitable for 
tumors with a diameter of less than 200 μm while beta emitters can be used for tumors up to 
2-10 mm [5]. Because of the relatively long range of beta particles, cross radiation of 
neighbouring cells is an important mechanism of action using beta-RIT, while alpha-RIT is 
more dependent on a homogeneous tumor uptake. 
Thorium-227 is a novel radionuclide for alpha-RIT that can be produced in clinically 
relevant amounts from beta-decay of the long-term generator 227Ac [6,7]. The decay chain of 
227Th (227Th → 223Ra → 219Rn→ 215Po → 211Pb → 211Bi → 207Tl → 207Pb) emits 5 alpha and 2 
beta particles. The relatively long half-life of 227Th (T½ = 18.7 days) provides time for tumor 
cell targeting and excretion of non-bound RICs (227Th-conjugates) before large amounts of the 
daughter nuclide 223Ra is generated. 
The beta-emitter 177Lu (T1/2 = 6.7 days) has been successfully tested for beta-RIT in 
several clinical trials [8,9]. It can be produced by direct neutron activation of 176Lu, or via beta 
decay of reactor-produced 177Yb [10,11]. Lutetium-177 might be used in RIT of smaller sized 
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tumors because the energy of the beta particle is relatively low (resulting in shorter range in 
tissue) compared to other beta-emitters used for RIT [11]. 
One quarter of breast cancer patients overexpresses human epidermal growth factor 
receptor-2 (HER-2/neu) both at their primary and distant tumor sites [12]. The anti-HER-2 
humanized antibody trastuzumab (Herceptin®) is approved for patients with HER-2 
overexpressing breast cancer; both in the adjuvant and metastatic setting [13]. Patients with 
high HER-2 overexpression respond best to trastuzumab [14]. Use of trastuzumab as a carrier 
for either alpha- or beta-emitting radionuclides may enhance the effect of the treatment and 
may also enable treatment of patients with lower HER-2 overexpression [15]. 
Recently, 227Th- and 177Lu-labeled trastuzumab has been evaluated and showed 
promising results [16–20]. In the present study we have compared their therapeutic effects and 
toxicities in nude mice bearing breast cancer xenografts (SKBR-3). 
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Material and methods:  
Radiolabeling of 227Th and 177Lu 
Radiolabeling of trastuzumab (Roche, Basel, Switzerland) with 227Th was performed at Algeta 
ASA (Oslo, Norway). The p-SCN-Bn-DOTA (Macrocyclics Inc., Dallas, TX) was conjugated 
to trastuzumab, and the conjugate DOTA-Bn-trastuzumab was used in the following 227Th 
chelation reaction. The detailed conjugation and radiolabeling methods have previously been 
described [17]. 
Radiolabeling of trastuzumab with 177Lu (Perkin Elmer, Shelton, CT) was performed 
at the Norwegian Radium Hospital. Freeze-dried DOTA-Bn-trastuzumab was dissolved in (10 
mg/ml) ammonium acetate buffer (pH 5) (VWR International, Leuven, Belgium).185 MBq 
177Lu was added to 0.5 mg DOTA-Bn-trastuzumab and the reaction was done by shaking at 
42 ºC for one hour. The RIC was purified twice on a 10 DG column (Bio-Rad Laboratories, 
USA) using PBS (PAA Laboratories GmbH, Pasching, Austria) added 5 mM EDTA (Sigma-
Aldrich Co., 3050 Spruce Street, St. Louis) and 0.25 % foetal calf serum (FCS) (PAA 
Laboratories GmbH, Pasching, Austria) as running buffer. 
 
Immunoreactivity and specific activity  
The estimation of immunoreactive fraction (IRF) of 227Th-trastuzumab was done by 
measuring the cell bound activity in a one point binding assay. Two vials with SKOV-3 cell 
concentrations up to 2×107 cells/mL in 200 μL PBS were used. In one vial, four million cells 
were blocked with 0.1 mg trastuzumab for 15 minutes at 37 ºC. The four million cells in the 
other vial were not blocked. About 500 cpm (5-9 ng) of 227Th-trastuzumab was added to each 
vial and the cells were incubated for 2 hours at 37 ºC before washing and measuring 
radioactivity using an automated gamma counter (Wizard, Packard Instrument Co., Downers 
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Grove, IL). The IRF of 227Th-trastuzumab was 62-90 %. The specific activity of 227Th-
trastuzumab was 1000-1600 kBq/kg [17]. 
A modified Lindmo method [21] was used to determine the immunoreactive fraction 
(IRF) of 177Lu-trastuzumab. Cell concentrations of up to 3 x 109 cells/ml were used; one vial 
of each concentration was blocked with 0.5 mg trastuzumab for 10 minutes at 4 ºC and 2-10 
ng 177Lu-trastuzumab was added. After incubation with shaking at 4 ºC for 1.5-2 hours, the 
cells were washed twice and cells, supernatant and wash were counted in a gamma counter 
(Cobra-gamma, Packard Instrument Co. Downers Grove, IL). For 177Lu-trastuzumab, the 
specific activity was 100-125 MBq/mg and the IRF was 90-94 %. 
 
Animals 
Eight to 12 weeks old female Balb/C nu/nu (NCR) mice (institutionally bred), with an average 
weight of 19-25 g, were used in the study. Subcutaneous injection of 0.05 ml Zoletil® mix 
(Virbac, Carros Cedex, France) was used for anaesthesia before HER-2 positive breast cancer 
(SKBR-3) tissue was implanted subcutaneously. Tumor xenografts were originated from 
human breast cancer cells from the American Type Culture Collection (ATCC, Manassas, 
VA, USA). The animals were maintained under pathogen-free conditions, and food and water 
were supplied ad libitum. Mice with growing tumor of diameters between 4 and 8 mm were 
included in the experiments. The mice were killed by cervical dislocation. 
 
Ethics information 
Procedures and experiments involving animals in this study were approved by the National 
Animal Research Authority (Permit ID: 2202) and carried out according to the European 
Convention for the Protection of Vertebrate Animals used for Experimental and other 
Scientific Purposes.  
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Biodistribution of 227Th and 177Lu labeled trastuzumab 
227Th-trastuzumab (10 kBq) or 177Lu-trastuzumab (1 MBq) (100 μl) was injected into mice via 
the tail vein. For each conjugate and time point a total of 4 to 6 animals were autopsied. 
Radioactivity content and weight of tissues were measured. 
Thorium-227 and 223Ra were measured using a solid-state photon well germanium 
detector (GCW6021, Canberra, Meriden, CT) coupled to a digital gamma ray spectrometer 
and analyzed using the computer software Apex™ version 1 (Canberra). For 227Th, the 236 
keV (abundance 17.6 %) and 256 keV γ-ray (abundance 9.5 %) lines were used and for 223Ra 
the 154 keV (abundance 5.7 %), 269 keV (abundance 13.9 %), 324 keV (abundance 4 %) and 
338 keV (abundance 2.8 %) γ-ray lines were used [17].  
The 177Lu-trastuzumab samples were measured with a calibrated gamma detector 
(Cobra-gamma). Samples of the injectates (10 %) were used as references in the measurement 
procedure. 
Calculation of dose 
The total number of disintegrations in various tissues from the time of injection of the 
preparation until no significant activity was left in the body was estimated by calculation of 
the area under the activity concentration versus time curves (AUC).  
The absorbed radiation dose and dose rate for 227Th-trastuzumab [17] were calculated 
assuming dose contributions only from α-particle emissions with a mean D-energy (Eα) of 5.9 
MeV for 227Th and 26.4 MeV for 223Ra with daughters in equilibrium [22]. It was assumed 
that there was a 100 % uniform absorption of the α-dose within a tissue and the probability of 
cross irradiation between adjacent organs was not taken into consideration.  
The absorbed radiation dose and dose rate for 177Lu-trastuzumab was calculated 
assuming dose contributions only from β-particle emissions with a mean energy of 134.2 keV 
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[23]. It was assumed that the absorbed fraction and cross irradiation (AF(WT)) of E-particles 
in the organs varied according to Table 13 in Miller et al.[24].  
Thus the total dose to each organ could be estimated by Eq 1 and 2: 
Dose (227Th-trastuzumab) = AUC0∞·Eα (227Th) + AUC0∞·Eα (223Ra+daughters)       (1) [17] 
Dose (177Lu-trastuzumab) = AUC0∞·Eβ (177 Lu).AF (WT)                                            (2) 
 
Therapeutic studies 
Mice were injected i.v. with sterile filtered solutions of NaCl (control), 200, 400, 600 or1000 
kBq/kg of 227Th-trastuzumab, or 40 or 200 MBq/kg of 177Lu-trastuzumab in 100 μl PBS. 
Tumor growth and mouse weight were assessed 3 times during the week before injection and 
in the first 3 weeks after injection; thereafter, weight, growth and survival were assessed 2 
times a week. Mice with tumor diameter larger than 20 mm were sacrificed. 
 
Calculation of relative biological effect 
The number of days after injection of RICs needed for the tumor to reach the normalized 
tumor volume (NTV) of 500 mm3 and 1000 mm3 was determined for each treatment and 
cumulative absorbed radiation doses to tumor were calculated for these time points. 
Treatment–induced percent increase in number of days to grow to 500 mm3 and/or 1000 mm3 
were plotted against the cumulative absorbed radiation dose. The doses needed to induce a 50 
% increase or 100 % increase in the number of days to grow to 500 mm3 and/or 1000 mm3 
were determined. Relative Biological Effect (RBE) was calculated by dividing the dose for 
227Th-trastuzumab by the dose for 177Lu-trastuzumab.  
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Toxicity evaluation  
Kidney function and liver enzyme activity, blood cell counts and histopathological changes 
were assessed. Approximately 100-200 μl blood was collected from the vena saphena lateralis 
in 500 Pl EDTA-coated tubes (Microtainer K2E tubes, Becton, Dickinson, NJ) for blood 
counting. Blood samples were taken the day before injection and at 3, 6, 9 and 12 weeks after 
start of the study. In addition, when the mice had to be killed due to tumor size or weight loss, 
blood samples were collected by heart puncture and added to EDTA-coated tubes and to 
lithium coated tubes (Microtainer LH tubes, Becton, Dickinson) for analysis of clinical 
chemistry parameters. Blood cells were counted in an automatic blood counter (Scil Vet abc 
blood machine, Horiba group, Montpellier, France). Clinical chemistry strips were used to 
assess the serum aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline 
phosphatase (ALP) and urea level (Reflotron, Roche Diagnostics GmbH, Mannheim, 
Germany). Blood serum samples (30 μl) were analyzed by serum analyzer (Reflovet, Roche, 
Diagnostics). 
The lungs, heart, kidneys, spleen, small intestine, large intestine, liver, femur, skull 
and tumor were fixed with formalin, cut in 5 μm slices, stained with hematoxylin and eosin 
and analyzed to detect pathological changes. 
Statistical analysis  
Statistical analysis of the survival experiments was done using Mantley Cox log-rank test by 
SPSS version 16. Student t-test was used to determine significance, p ≤ 0.05.  
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Results: 
Biodistribution 
Table 1 and 2 show the biodistribution of 227Th-trastuzumab and 177Lu-trastuzumab, 
respectively. The blood levels were 27 ± 3 % ID/g and 25 ± 1 % ID/g one hour after injection 
of 227Th-trastuzumab and 177Lu-trastuzumab, respectively. The maximum decay-adjusted 
uptake of 227Th-trastuzumab in tumor (34 ± 25 % ID/g) occurred 3 days after injection. Upon 
injection of 227Th-trastuzumab the 223Ra content is very low, for instance only 26 Bq/g in the 
blood 1 h after injection of 400 kBq/kg 227Th-trastuzumab [17]. However, as 227Th decays the 
amount of 223Ra increases, and 223Ra is either excreted, taken up by bone or retained in the 
tumor. After 21 days the uptake in femur and skull was 642 Bq/g and 586 Bq/g and the 
content of 223Ra in tumor was 135 Bq/g [17]. The maximum decay-adjusted uptake of 177Lu-
trastuzumab in tumor (40 ± 18 % ID/g) occurred 7 days after injection. There were no 
statistically significant differences in uptake of 227Th-trastuzumab and 177Lu-trastuzumab in 
other organs for the 24 h, 4 day and 7 day time points. In other studies the peak levels of 
177Lu-trastuzumab in SKBR-3 tumor xenografts and 177Lu-pertuzumab in SKOV-3 tumors 
were achieved 3 days after administration [16,25].  
Figure 1A and B show the absorbed dose rate in the blood, femur and tumor after 
injection of 400 kBq/kg 227Th-trastuzumab and 40 MBq/kg 177Lu-trastuzumab, respectively. 
The dose rate was calculated assuming dose contribution only from alpha particles from 
227Th, 223Ra and daughters. Absorbed dose rate decreased rapidly for blood while increased 
for tumor in the first 24 hours after injection for both RICs. In tumor tissue the absorbed dose 
rate increased gradually for 227Th-trastuzumab injection and more rapidly for 177Lu-
trastuzumab. The apparent difference in timing for peak dose rate was not statistically 
significant. Tumor dose rate for 177Lu-trastuzumab was almost similar from 24 h to 7 days 
time points (Figure 1B). Maximum dose rate in tumor was 413 ± 273 mGy/day for 400 
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kBq/kg 227Th-trastuzumab. The absorbed dose rate in femur increased to its maximum level 
(257 ± 65 mGy/day) at 21 days after 227Th-trastuzumab injection due to relocalization of 223Ra 
to femur, introducing a dose contribution from both 223Ra and its daughters. Maximum dose 
rate in tumor was 357 ± 213 mGy/day for 40 MBq/kg 177Lu-trastuzumab.  
Therapeutic effects  
Growth of SKBR-3 tumor xenografts in mice treated with different dosages of alpha-particle 
emitting 227Th-trastuzumab was compared with different dosages of beta-particle emitting 
177Lu-trastuzumab and with saline as control (Figure 2 and Table 3). Dose dependent growth 
inhibition of SKBR-3 tumor xenografts was observed for both 227Th-trastuzumab and 177Lu-
trastuzumab. 400 kBq/kg 227Th-trastuzumab and 40 MBq/kg 177Lu-trastuzumab both resulted 
in an absorbed dose of approximately 3 Gy to tumor. However, the tumor growth in mice 
treated with 400 kBq/kg 227Th-trastuzumab (2.9 Gy to tumor) was considerably inhibited and 
the average delay to grow to a tumor volume of 500 mm3 was 23 ± 10 days in comparison to 
the control. The tumor growth was not affected by 40 MBq/kg 177Lu-trastuzumab (3 Gy to 
tumor), however a significant anti-tumor effect was observed after injection of 200 MBq/kg 
177Lu-trastuzumab (16 Gy to tumor). Hence, growth delay to reach a tumor volume of 500 
mm3 was 4 ± 11 days, 45 ± 7 days, and 38 ± 8 days for 200 kBq/kg, 600 kBq/kg and 1000 
kBq/kg of 227Th-trastuzumab, respectively, while it was 74 ± 9 days after 200 MBq/kg 177Lu-
trastuzumab injection (Figure 2 and Table 3). The tumor volume for each treatment group was 
normalized to the same tumor volume at the time of injection.  
Survival of mice treated with 200, 400, 600 and 1000 kBq/kg 227Th -trastuzumab and 
200 MBq/kg 177Lu-trastuzumab was significantly longer than observed in untreated control (p 
< 0.05) (Figure 3). No significant difference in survival of mice was observed between 40 
MBq/kg 177Lu-trastuzumab and control groups (p > 0.05). 
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Relative biological effectiveness 
The percent increase in number of days to reach a tumor volume of 500 mm3 and 1000 mm3 
was plotted against the cumulative radiation dose for the corresponding time (Figure 4A and 
B). Two levels of biologic effects; 50 % and 100 % increase in the number of days to reach 
the chosen normalized tumor volume, were used as end points for calculation of RBE. RBE 
was 2.8 for 100 % increase and 2.2 for 50 % increase in the number of days to grow to 500 
mm3and RBE was 2.5 for 100 % and 2.2 for 50 % increase in the number of days to grow to 
1000 mm3. 
Toxicity of the treatments 
Leukocyte and platelet counts in all treatment groups remained within normal physiological 
range for NCR nude mice [26] with a transient decrease of leukocyte count, between 3 to 9 
weeks after the start of treatment while platelets remained unaffected (Figure 5A and B). This 
transient decrease of WBC counts after higher dosage administration was statistically 
significant in comparison to control (p < 0.05). This short time reduction of WBC count was 
less after 177Lu-trastuzumab (200 MBq/kg) than the highest dosages of 227Th-trastuzumab 
(600 and 1000 kBq/kg) (Figure 5A). Similar decrease of WBC counts was seen for 200 
MBq/kg 177Lu-trastuzumab and 400 kBq/kg 227Th-trastuzumab (Figure 5A), both giving a 50 
% decrease in the number of white blood cells after 3 weeks. However, 177Lu-trastuzumab 
was 3 times more efficient in inhibiting tumor growth than 227Th-trastuzumab at these dosages 
(200 MBq/kg 177Lu-trastuzumab and 400 kBq/kg 227Th-trastuzumab), which indicates that 
although the RBE was higher for 227Th-trastuzumab, the therapeutic index was higher for 
177Lu-trastuzumab. 
Bone marrow morphology after administration of 227Th-trastuzumab (200, 400, 600 
and 1000 kBq/kg), 40 MBq/kg and 200 MBq/kg of 177Lu-trastuzumab was analyzed and 
compared to the control. No pathological findings in hematopoietic tissue (bone marrow) 
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were seen in this study even at highest therapeutic dosages of both RICs (data not shown). 
Blood urea level (BUL), and activity of alanine aminotransferase (ALT), alkaline phosphatase 
(ALP) and aspartate aminotransferase (AST) were found to be within the normal 
physiological range of these parameters in NCR Nude mice for all treatments [26] (data not 
shown). Weight loss was not observed in any of the treatment groups compared to control 
except for 1000 kBq/kg 227Th-trastuzumab. In this group, 5 mice out of 8 had to be killed due 
to weight loss (data not shown). In this study, weight loss was considered if mice losses 
weight either more than 15 % (for 1000 kBq/kg 227Th-trastuzumab) or 20 % (for rest of the 
treatment groups) from maximum tumor free body weight.  
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Discussion: 
The aim of the present study was to compare the biodistribution, normal tissue toxicity and 
therapeutic effect of the alpha-particle emitting 227Th-trastuzumab and the beta-particle 
emitting 177Lu-trastuzumab in mice with HER2-expressing SKBR-3 breast cancer xenografts. 
Based on the temporary decrease in WBC count, the therapeutic index was higher for 177Lu-
trastuzumab compared to 227Th-trastuzumab. In contrast, the high LET emitting 227Th-
trastuzumab was 2.8 fold more efficacious against SKBR-3 tumors compared to the low LET 
emitting 177Lu-trastuzumab when compared at the same relatively low dose to tumor (3 Gy). 
No severe bone marrow or normal organ toxicities were seen in this study after administration 
of both RICs. However, a mild and transient WBC reduction was seen with 227Th-
trastuzumab. 
Injection of 200 MBq/kg 177Lu-trastuzumab or 400 kBq/kg 227Th-trastuzumab resulted 
in similar reduction of WBC count at 3 weeks time point. The therapeutic efficacy of 200 
MBq/kg 177Lu-trastuzumab was three times higher than for 400 kBq/kg 227Th-trastuzumab. 
These results can be expected because the absorbed radiation dose to the tumor was 5.3 times 
higher for 200 MBq/kg 177Lu-trastuzumab than for 400 kBq/kg 227Th-trastuzumab (16 vs 3 
Gy). A similar therapeutic effect was also seen with 200 MBq/kg 177Lu-pertuzumab in mice 
with SKOV-3 xenografts [25].  
Tumors treated in the present study were much larger (4-8 mm) than considered ideal 
for short ranged alpha particle 227Th-trastuzumab and more suitable for 177Lu-trastuzumab, 
which may partly explain the difference in therapeutic index. Short ranged 227Th-trastuzumab 
therapy is suitable for small sized tumors (less than 200 μm) and due to cross fire and long 
range, 177Lu-trastuzumab would be suitable for larger sized tumors. Therefore, it can be 
anticipated that the therapeutic index in humans would have been higher for 227Th-
15 
 
trastuzumab than for 177Lu-trastuzumab because of small micrometastatic lesions resulting in 
more even dose distribution.  
Administration of 600 and 1000 kBq/kg 227Th-trastuzumab resulted in modest and 
temporary decrease of WBC, possibly due to bone localization of 223Ra and its daughters, 
slightly more than seen after 200 MBq/kg of 177Lu-trastuzumab. Radium-223, generated from 
227Th decay, could have been produced either from tumor cell-internalized [18] or tumor cell 
bound 227Th-trastuzumab in the tumor tissue. 
 A dosage of 40 MBq/kg of 177Lu-trastuzumab and 400 kBq/kg of 227Th- trastuzumab 
resulted in the same absorbed radiation dose to the tumor (3 Gy). 40 MBq/kg 177Lu-
trastuzumab neither inhibited the tumor growth nor improved the survival of mice, while 400 
kBq/kg 227Th-trastuzumab improved survival by 166 % and growth inhibition by 253 %. 
Interestingly, slightly higher dosage (74 MBq/kg) of 177Lu-d9MAb used for treatment of mice 
with intraperitoneal gastric carcinoma cells (HSC45-M2) have been shown to result in 
prolongation of survival [27]. The difference in the tumor model and mode of administration 
(i.p. vs i.v.) of 177Lu- d9MAb could explain the different results.  
The RBE of high LET emitting 227Th-trastuzumab was 2.8 fold higher than for the low 
LET emitting 177Lu-trastuzumab. Similar results were also obtained in our previous study; 
administration of low dose 227Th-rituximab was more effective per dose unit as compared to 
both low LET RIT and X-radiation [28].  
No severe bone marrow or normal organ toxicity was seen in this study after 
administration of both RICs. However, a mild toxic effect of transient WBC reduction was 
seen with 227Th-trastuzumab. The low bone marrow toxicity of 227Th-trastuzumab could be 
due to the short range of alpha particles from 227Th, 223Ra and daughters. With similar 
localization to bone, the long range beta-emitter Strontium-89 has been found to be more 
toxic than the short range 223Ra [29]. The long half life of 227Th and 227Th-trastuzumab 
16 
 
internalization, after binding to HER2, results in either excretion or internalization of larger 
amounts of 227Th before 223Ra is generated, which might reduce its localization to bone. A 
recently conducted and reviewed phase III trial [30,31] with other clinical studies [29,32] 
have also shown that 223Ra is well tolerated by breast and prostate cancer patients. These 
clinical results show that the accumulation of small amounts of 223Ra in the bone marrow is 
tolerable and is also compatible with our previous data in animal model [33]. 
 
Conclusion: At the same, relatively low absorbed radiation dose, the alpha-particle 
emitting 227Th-trastuzumab was 3 times more efficient in inhibiting tumor growth than the 
beta-particle emitting 177Lu-trastuzumab. However, at the same level of transient reduction in 
WBC count 177Lu-trastuzumab was almost 3 times more efficient in inhibiting tumor growth 
than 227Th-trastuzumab.  
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Figure Legends 
Figure 1. Absorbed radiation dose rates 
Dose rates to blood, tumor and femur after injections of 400 kBq/kg 227Th-trastuzumab (A) 
and 40 MBq/kg 177Lu-trastuzumab (B). Error bars represent SD.  
Data for 227Th-trastuzumab has previously been published [17] except 1000 kBq/kg 227Th-
trastuzumab (accepted for publication in PLoS ONE). 
Figure 2. Normalized average tumor volumes versus time after 
treatment 
Normalized mean tumor size versus time after a single injection of saline (n = 23), 200 
kBq/kg (n = 10), 400 kBq/kg (n = 11), 600 kBq/kg (n =12) and 1000 kBq/kg (n = 8) 227 Th-
trastuzumab and 40 MBq/kg (n = 10) and 200 MBq/kg (n = 9) 177Lu-trastuzumab.  
Error bars represent SE. The tumor sizes were not removed from the calculation of mean 
tumor volume when the mice were killed. Data for 227Th-trastuzumab therapy has previously 
been published [17] except 1000 kBq/kg 227Th-trastuzumab (accepted for publication in PLoS 
ONE). 
Figure 3. Survival of mice with tumor xenografts 
Survival of mice after a single injection of saline (n = 23), 200 kBq/kg (n = 10), 400 kBq/kg 
(n = 11), 600 kBq/kg (n =12) and 1000 (n = 8) kBq/kg 227 Th-trastuzumab and 40 MBq/kg (n 
= 10) and 200 MBq/kg (n = 9) 177Lu-trastuzumab. Median survival times of treated mice were 
compared using Kaplan Meier log-rank test. 
Mice with tumor diameter greater than 20 mm were killed. Data for 227Th-trastuzumab has 
previously been published [17] except 1000 kBq/kg 227Th-trastuzumab (accepted for 
publication in PLoS ONE). 
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Figure 4. Treatment induced growth delay  
Percent increase in number of days to reach a normalized tumor volume of 500 mm3 (A) and 
1000 mm3 (B) for 227Th-trastuzumab and 177Lu-trastuzumab.  
Data for 227Th-trastuzumab therapy has previously been published [17] except 1000 kBq/kg 
227Th-trastuzumab (accepted for publication in PLoS ONE). 
Figure 5. Bone marrow toxicity 
Bone marrow toxicity assessment in the form of white blood cell (A) and platelet count (B) 
analysis as function of time after injection of NaCl, 200 kBq/kg, 400 kBq/kg, 600 kBq/kg and 
1000 kBq/kg of 227Th-trastuzumab and 40 MBq/kg and 200 MBq/kg of 177Lu-trastuzumab. 
Error bars represent SD. Data for 227Th-trastuzumab toxicity has previously been published 
[17] except 1000 kBq/kg 227Th-trastuzumab (accepted for publication in PLoS ONE). 
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